Poll Finding

Examining LGBTQ+ Adults’ Experiences with Health Care Costs and Access

Published: Aug 27, 2026

Key Takeaways

  • LGBTQ+ adults face significantly greater challenges accessing and affording health care compared to their non-LGBTQ+ peers. They are more likely to postpone or skip needed care (58% vs. 38%), forgo prescription medications due to cost (22% vs. 12%), and struggle to pay medical bills (30% vs. 21%).
  • Cost-related barriers to care are especially pronounced among certain segments of the LGBTQ+ population, most notably trans adults, younger LGBTQ+ adults, those with lower incomes, and those without health coverage. Eight in ten (82%) trans adults, three-quarters (77%) of LGBTQ+ adults without health coverage, and two-thirds (68%) of those under age 30 report not getting needed health care in the past 12 months either because they couldn’t get an appointment, couldn’t afford the cost, or for another reason. Additionally, larger shares of LGBQ+ women than men report skipping or delaying care in the past year (63% vs. 46%).
  • While trans adults represent a small share of the total LGBTQ+ population, they experience outsized barriers to affording care and other access issues. Compared with other LGBQ+ groups, trans adults report the highest rates of difficulty finding providers with available appointments (53%), not taking prescription medications because of cost (39%), worsening health from postponed care (45%), struggling with medical bills (42%), and experiencing insurance delays or denials (61%). Trans adults experience these greater barriers to health cost and access even when controlling for other demographic variables such as age, income, and insurance status.
  • Health care costs create significant financial strain for many LGBTQ+ adults. Three in ten (30%) report problems paying medical bills in the past year, and one in five (19%) say they cut back on household necessities such as food or clothing to pay for health care costs. Financial burdens are particularly common among younger adults, those with lower incomes, and those without health coverage.
  • Having health insurance does not guarantee timely access to care. About three in ten LGBTQ+ insured adults report that their insurance delayed or denied coverage for recommended care in the past two years, a more widespread experience than among non-LGBTQ+ insured adults, with particularly high rates among trans adults and those covered by Medicaid or those with ACA marketplace coverage.

Understanding the Challenges LGBTQ+ Adults Face Affording Health Care

LGBTQ+ adults in the U.S. are a growing population who have historically faced health disparities in terms of both wellbeing and health care access and affordability. Previous research has found that LGBTQ+ adults are more likely than their non-LGBTQ+ peers to experience barriers to obtaining needed care, to struggle to afford health care costs, and to delay or forgo care because of cost. These affordability challenges often intersect with and may even be a driver of broader health disparities, including poorer mental and physical health outcomes, particularly among trans adults.

Understanding the financial challenges LGBTQ+ adults face when accessing health care can help identify persistent gaps in affordability and inform efforts to improve access to needed care and coverage.

LGBTQ+ definition and demographics

The LGBTQ+ sample included in this analysis is comprised of 2,640 adults, including 52% who identify as bisexual, 21% as gay men, 9% as lesbian women, 9% as transgender, and 9% who use some other term to identify themselves. The analysis is broken out by transgender (trans) adults (9%), lesbian, gay, bisexual or other queer identifying men (39%), and lesbian, gay, bisexual, or other queer identifying women (50%).

The LGBTQ+ community is not a monolith and beyond differences related to sexual orientation and gender identity, health care experiences can vary widely depending on age, income, and insurance status, among other factors. This analysis also examines differences by these factors. For example, regardless of LGBTQ+ identity, women tend to have more interactions with the health care system than men and therefore, may have more cost or access issues. In addition, trans adults are more likely than other groups to face barriers in health care, including discrimination and lack of providers trained to handle the health needs of trans adults. Subgroups of the LGBTQ+ population, including trans adults or older adults usually make up too small a share of national survey samples to allow for statistically reliable analysis. The large sample size of this survey provides a unique opportunity to examine these differences.

This report also compares the experiences of LGBTQ+ adults with their non-LGBTQ+ counterparts. A caveat to these comparisons is that there are key demographic differences between LGBTQ+ and non-LGBTQ+ adults that may contribute to differences in measures of health care cost and access between these populations. LGBTQ+ people are generally younger than the U.S. population overall, have lower incomes, and are somewhat more likely to be uninsured. Therefore, some findings might be more reflective of income or coverage differences, for example, than LGBTQ+ identity, though those factors are certainly intertwined. See appendix for a more detailed analysis of the demographic characteristics of the LGBTQ+ community.

Delays in Health Care for LGBTQ+ Adults

Six in ten LGBTQ+ adults (58%) say they have skipped or postponed needed health care in the past year, greater shares than their non-LGBTQ+ counterparts (38%). This includes more than four in ten (43%) LGBTQ+ adults who say they’ve skipped or delayed getting needed care because of the cost and about three in ten who said it was due to their inability to get an appointment (28%) or for some other reason (29%). LGBTQ+ adults are nearly twice as likely as non-LGBTQ+ adults (26%) to say they’ve skipped or delayed getting needed care because of the costs.

Compared to other LGBQ+ adults, trans adults are more likely to report they have put off care in the past year because of cost or other issues (82%). At least half of trans adults say they skipped or postponed getting needed health care because of the cost (56%), because they couldn’t find a doctor or health care provider with appointments available (53%), or they skipped or postponed for any other reasons (48%). There may be many reasons why trans adults are more likely to skip or delay care, but a recent KFF/Washington Post Trans Survey found significant barriers for trans adults in getting needed health care, including providers not being properly educated to provide appropriate care.

Beyond trans adults, larger shares of LGBQ+ women than men report skipping or postponing care in the past year (63% vs. 46%). This includes half of LGBQ+ women who say they skipped or postponed needed care because of the cost (compared to a third of LGBQ+ men), and roughly a third of LGBQ+ women who say they skipped or postponed care because they couldn’t get an appointment (31% vs. 19% of LGBQ+ men) or for any reason besides cost or not being able to get an appointment (32% vs. 21% of LGBQ+ men). Across all LGBTQ+ groups, non-LGBTQ+ adults less commonly reported skipping or postponing care.  

Many socioeconomic and demographic factors can predict delaying or skipping care, but LGBTQ+ adults are more likely to skip or delay care even when controlling for race and ethnicity, insurance coverage, age, income, and education, suggesting this population group may have unique struggles in accessing needed health care. The differences reported in this analysis between LGBTQ+ adults and non-LGBTQ+ adults hold even when controlling for these demographic characteristics.

Six in Ten LGBTQ+ Adults Have Missed Needed Care Because of Cost or Other Reasons in the Past Year (Split Bars)

Among all LGBTQ+ adults, two-thirds (68%) of those under age 30 report having put off needed care in the past year, higher than the shares of older LGBTQ+ adults who report this. While age is a significant predictor of putting off care regardless of sexual identity, LGBTQ+ adults under age 30 are twenty percentage points more likely to report putting off care than non-LGBTQ+ adults in the same age range (48%). In fact, across most age groups, LGBTQ+ adults are more likely to report putting off or postponing needed care than their non-LGBTQ+ counterparts, except for those 65 and older. The difference between LGBTQ+ and non-LGBTQ+ adults levels out among those age 65 and older, which may be due to several factors, such as increased medical care among older adults and Medicare eligibility.

LGBTQ+ Adults Are More Likely Than Non-LGBTQ+ Adults in Same Age Groups To Report Missing Care, Including More Than Two-Thirds of Those Under Age 30 (Split Bars)

Insurance and income also play a role in accessing care. Three in four (77%) LGBTQ+ adults without health insurance report having missed or delayed care in the past year for any reason, compared to six in ten LGBTQ+ adults with health insurance. Fewer non-LGBTQ+ adults than LGBTQ+ adults without health insurance report experiencing any of the following in the past year (65% vs. 77% of uninsured LGBTQ+ adults).

Three-Quarters of LGBTQ+ Adults Without Insurance Report Missing Care for Any Reason in the Past Year (Split Bars)

Similarly, about six in ten LGBTQ+ adults with household incomes under $40,000 a year (59%) or between $40,000 and $99,999 a year (63%) say they skipped or postponed needed care, compared to half of those with annual incomes of $100,000 or more. Even among the highest income groups or those with health insurance, LGBTQ+ adults are more likely than non-LGBTQ+ adults to say they skipped or delayed needed care in the past year.

LGBTQ+ Adults With Lower Household Incomes Are More Likely To Have Missed Needed Care in the Past Year (Split Bars)

Substantial shares of LGBTQ+ adults report postponing their care worsened their health, and that number is especially pronounced among trans adults. Three in ten (29%) LGBTQ+ adults say their health got worse because they skipped or delayed care, which is about twice the share of non-LGBTQ+ adults who report the same (14%). This experience is more common among LGBQ+ women (34%) than LGBQ+ men (20%). Almost half (45%) of trans adults say they delayed or skipped care and their health got worse as a result.

Three in Ten LGBTQ+ Adults, Including Almost Half of Trans Adults Report Their Health Worsened Because They Didn’t Get or Postponed Care (Stacked Bars)

The share who say their health got worse due to postponing care also rises to roughly a third of uninsured LGBTQ+ adults (35%) and those under age 30 (35%). One-third (33%) of LGBTQ+ adults with household incomes of less than $40,000 report that their health got worse because of postponed care.

Younger, Uninsured, Lower Income LGBTQ+ Adults More Likely To Say Their Health Worsened as a Result of Postponed Care (Stacked Bars)

Impacts of Cost on Prescription Medications

Cost barriers also affect prescription medication behavior, including among LGBTQ+ adults, with about a fifth of LGBTQ+ adults (22%) saying they’ve cut pills in half, skipped doses of a medication, or decided not to fill a prescription because they couldn’t afford the cost (compared to 12% of non-LGBTQ+ adults). Trans adults (39%), LGBTQ+ adults without insurance (28%), LGBQ+ women (25%), and younger LGBTQ+ adults (23% of those under age 30), are the most likely to report that they didn’t take their prescription medication as prescribed due to cost.

In addition, around a quarter of LGBTQ+ adults with lower incomes report cutting pills in half, skipping doses of medications, or not filling a prescription in the past year due to cost, including 27% of those with a household income of less than $40,000 a year, and 24% of those with incomes between $40,000 and $99,999 a year, compared to around one in ten (12%) of LGBTQ+ adults with incomes of $100,000 or more a year.

A Quarter of LGBTQ+ Adults Report Not Taking Medications As Prescribed in the Last Year Because of the Cost (Split Bars)

Difficulty Paying Medical Bills

Substantial shares of LGBTQ+ adults also report struggling with medical bills. Three in ten LGBTQ+ adults say they have had problems paying for or were unable to pay a medical bill, including bills for doctors, tests or labs, or medication in the past 12 months, higher than the 21% of non-LGBTQ+ adults who say the same. This includes four in ten (42%) trans adults, over a third (36%) of LGBQ+ women and two in ten (21%) LGBQ+ men.

Problems with bills can lead to important financial consequences for many LGBTQ+ adults. Two in ten (19%) LGBTQ+ adults, including two in ten (22%) LGBQ+ women and roughly one in ten (13%) LGBQ+ men say they’ve had to cut back on household expenses like food, clothing, or other basic household items in order to pay for health care costs. This experience is more common among trans adults, over one quarter of whom (28%) report the same. Overall, LGBTQ+ adults report they have cut back on necessities to pay for health care costs more commonly than non-LGBTQ+ adults (13%).

Three in Ten LGBTQ+ Adults Had Problems Paying Medical Bills in the Past Year and Significant Shares Cut Back on Household Expenses To Pay Costs (Split Bars)

Younger LGBTQ+ adults and those with lower household incomes, two groups with considerable overlap, are among the most likely to report problems paying medical bills in the past year, with around a third of those under age 30 (33%), between 30 and 49 (34%), those with incomes of less than $40,000 a year (35%) or between $40,000 and $99,999 (35%) reporting they had problems paying or an inability to pay for any medical bills in the past year. Individuals earning over $100,000 annually and those 65 and older, who are largely covered by Medicare, are less likely to report such problems.

Younger LGBTQ+ adults and those with lower incomes are also more likely to report cutting back on expenses because of their problems paying medical bills. Overall, a quarter (24%) of LGBTQ+ adults with household incomes less than $40,000 a year say they have cut back on household expenses like food, clothing or other basic household items to pay for health care costs, compared to two in ten (19%) LGBTQ+ adults with incomes between $40,000 and $99,999 and one in ten (11%) of those with incomes of $100,000 or more a year.

Younger LGBTQ+ adults are also more likely to report cutting back on expenses because of trouble paying medical bills, including two in ten LGBTQ+ adults under age 30 and between ages 30 to 49 (21% for each) compared to one in ten (13%) LGBTQ+ adults ages 50 to 64 and one in twelve (8%) of those ages 65 and older.

Younger LGBTQ+ Adults, Those With Lower Incomes Are More Likely To Have Problems Paying Bills and To Cut Back To Pay for Costs (Split Bars)

Insurance Delays or Denials

Treatments or medications recommended by a provider may be delayed, and in some cases, an insurance company may deny coverage for the recommended medication or treatment after or during the care process. While insurance coverage helps some LGBTQ+ adults deal with access and cost issues, many face other challenges such as delayed or denied care.

Roughly one-third of insured LGBTQ+ adults say their insurance company denied coverage (32%) or delayed (30%) their ability to get a health care service, treatment, or medication that their doctor prescribed in the past two years. Four in ten say coverage has either been delayed or denied. These shares are substantially higher than among non-LGBTQ+ adults, about a quarter (26%) of whom say they’ve experienced a denial of service (21%) or delay (17%) in the past two years.

These experiences are particularly common among trans adults, roughly six in ten (61%) of whom say they’ve been delayed (53%) or denied (45%) coverage by their insurance for a service, treatment, or medication prescribed by their doctor in the past two years.

Four in Ten Insured LGBTQ+ Adults, Including Larger Shares of Trans Adults Report Their Insurance Company Has Delayed or Denied Needed Coverage in the Past Two Years (Split Bars)

Delays and denials of coverage for LGBTQ+ adults vary based on what type of insurance they have. Individuals with either self-purchased plans or Medicaid report experiencing these most often. Roughly half (48%) of LGBTQ+ adults under age 65 who have Medicaid (48%) or self-purchased insurance (46%) say their insurance company has denied or delayed health care services, treatments, or medications in the past two years. Given that Medicaid plays a larger role in covering LGBTQ+ people, this coverage difference may in partially explain some of the disparate challenges this group faces with delays and denials.  

Roughly four in ten (39%) LGBTQ+ adults under age 65 with employer-sponsored insurance say the same while just three in ten (28%) LGBTQ+ adults ages 65 and older with Medicare report experiencing recent delays and denials.

The share of LGBTQ+ adults with various types of health insurance who report delays or denials of needed care is larger than the share of non-LGBTQ+ adults who say the same. Roughly a third of those non-LGBTQ+ adults with Medicaid (33%) or self-purchased insurance (31%), around a quarter (26%) of those with employer-sponsored coverage, and around two in ten (18%) of non-LGBTQ+ adults who have Medicare and are ages 65 or older report these issues.

Large Shares of LGBTQ+ Adults Under Age 65 on Medicaid Report Delays or Denials of Needed Coverage in the Past Two Years (Split Bars)

The KFF Survey of Health Status and Caregiving was a series of questions designed and implemented by KFF with the SSRS Opinion Panel Mega-Omnibus. The survey was conducted May 4 – May 26, 2026, online and by telephone among a nationally representative sample of 25,873 U.S. adults in English (n=25,422) and in Spanish (n=451).

The SSRS Opinion Panel is a nationally representative probability-based panel where panel members are recruited randomly in one of two ways: (a) Through invitations mailed to respondents randomly sampled from an Address-Based Sample (ABS) through the U.S. Postal Service’s Computerized Delivery Sequence (CDS); (b) recruited via random digit dial (RDD) telephone sample of cell phone numbers connected to a prepaid cell phone. Both samples were provided by Marketing Systems Group (MSG). The combined sample was reached either online (n=24,875) or over the phone (n=998) based on the panelist’s stated preference. For the online panel component, invitations were sent to panel members by email followed by up to four reminder emails and up to two reminder text messages (if consented to receive SMS).

The questions designed by KFF were included as part of a multi-stakeholder effort designed to survey all individuals currently empaneled in the SSRS Opinion Panel, with each organization paying for and having independent editorial control over its survey questions.  Substantive questions from other outside stakeholders are redacted in this report. The SSRS survey team designed the questionnaire in order to minimize potential bias from question ordering. For more information, please contact SSRS.

Respondents who completed on the web received a $5 electronic gift card incentive (some harder-to-reach groups received a $10 electronic gift card). Respondents who completed the survey on the phone received $10 via a physical check in the mail. In order to ensure data quality, cases were removed if they failed two or more quality checks: (1) attention check questions in the online version of the questionnaire, (2) had over 10% item non-response, or (3) had a length of less than 30% of the mean length by mode. Based on this criterion, 69 cases were removed.

Data were weighted to represent adults 18+ in the United States. The Panel-wide base weight adjusts for the SSRS Opinion Panel recruitment and retention process. Because all current panelists (except 2026 recruits) were invited to participate and no further sampling was performed, no further adjustments to the Panel-wide base weight were necessary before applying it to the survey data.

With the Panel-wide base weight applied, the survey-data were weighted to match the sample’s demographic profile to the same target population parameters used in the calibration of the entire SSRS Opinion Panel. The demographic variables included in weighting for the general population sample are gender, age, race/ethnicity, and education (including interactions between these categories), as well as region, civic engagement, density, frequency of internet use, voter registration, political party identification, religion, household makeup, and home ownership. Final calibrated weights are trimmed at the 2nd and 98th percentiles to prevent individual interviews from having too much influence.

The margin of sampling error including the design effect for the full sample is plus or minus 1 percentage points. Numbers of respondents and margins of sampling error for key subgroups are shown in the table below. For results based on other subgroups, the margin of sampling error may be higher. Sample sizes and margins of sampling error for other subgroups are available on request. Sampling error is only one of many potential sources of error and there may be other unmeasured error in this or any other public opinion poll. KFF public opinion and survey research is a charter member of the Transparency Initiative of the American Association for Public Opinion Research.

GroupN (unweighted)M.O.S.E.
Total25,873±1 percentage point
 
LGBTQ+ adults2,640± 3 percentage points
LGBQ+ men963± 5 percentage points
LGBQ+ women1,440± 4 percentage points
Trans adults185± 11 percentage points
 
Non-LGBTQ+ adults23,233± 1 percentage point

 

A table shows the demographics of LGBTQ+ adults vs, non-LGBTQ+ adults. LGBTQ+ adults tend to be younger. For example, 37% of LGBTQ+ adults are 18-29 years old compared to 14% of non-LGBTQ+ adults. 5% of LGBTQ+ adults say they have a gender other than male or female. LGBTQ+ adults have a similar distribution related to educational attainment and race/ethnicity compared to non-LGBTQ+ adults. LGBTQ+ adults have lower incomes and are more likely to be democrats than non-LGBTQ+ adults.

VOLUME 53

Different State Regulatory Approaches Reflect Open Questions About AI Mental Health Tools


Highlights

States are taking different regulatory approaches to AI mental health tools in response to concerns about chatbots providing inaccurate or potentially dangerous advice. Laws and pending legislation in some states restrict AI from providing or advertising itself as therapy, while others focus on data protections, disclosures, and requirements for patient consent.


AI & Emerging Technology

States Move to Regulate AI Mental Health Tools with Varying Approaches

Concerns about AI chatbots providing wrong or potentially dangerous advice have prompted legislative activity in multiple states, following documented cases of chatbots responding inappropriately to mental health-related prompts and allegations that interactions with AI were a contributing factor in multiple suicides. AI chatbots have also been documented giving false or misleading responses to health-related questions, including cases where chatbots reinforced users’ inaccurate beliefs rather than correcting them. 

As about one in six (16%) adults, including three in ten (28%) adults under 30, say they have used AI tools for mental health information or advice in the past year, states have begun to use regulations to address these concerns, with different approaches:

  • Restricting AI from providing or claiming to be mental health care. Laws in Illinois, Nevada, Tennessee, Vermont, and Rhode Island have restricted the use of AI in mental health care, either by restricting what the tools are allowed to do or how they are allowed to be advertised. Most laws in this group still allow for licensed professionals to use AI in some capacity, including laws in Colorado and Vermont that both explicitly allow administrative use of AI tools.
  • Focusing on data protection and disclosure. A law in Utah passed last year takes a different approach than banning the use of unsupervised mental health chatbots outright. Instead, the state requires data privacy protections and safety disclosures while still permitting their use. An additional law in Rhode Island also includes a version of this in addition to bans on the independent practice of therapy by AI, requiring patient consent and notification when AI is used to document clinical visits. 
  • Pending legislation largely mirrors one of these approaches. Bills still pending in both California and Pennsylvania would restrict AI from independently delivering or recommending psychotherapy services. A separate bill in Pennsylvania and another in New Jersey focus on disclosure and data protections instead.

Why This Matters: The policy approaches have varied by state, with some states enacting restrictions on AI providing or representing itself as mental health care, while others have focused more on disclosure and data practices. The differences reflect an unresolved policy question about whether AI should primarily be treated as a clinical support tool, a consumer technology, or a form of health care requiring professional oversight.


Recent Developments

Executive Order Calls for Changes to Childhood Vaccine Schedule, As Officials Repeat Unsupported Claims About Vaccine Safety

What happened?

An executive order signed earlier this month by President Trump called for further changes to the childhood vaccine schedule, including calling for the combined MMR vaccine to instead be offered as separate shots, and new research on vaccine timing. Although the EO does not explicitly mention autism, Trump repeatedly connected vaccines to rising autism rates during an event for its signing, claiming that the action would lower autism diagnoses.

What does public opinion research tell us about people’s perceptions of vaccine safety?

KFF’s June 2026 Tracking Poll on Health Information and Trust found that two-thirds of adults (66%) had heard the false claim that MMR vaccines had been proven to cause autism, with about six in ten (61%) expressing some level of uncertainty, saying the claim was either “probably true” (22%) or “probably false” (39%). That level of uncertainty has remained stable since KFF began asking about belief in that false claim in June 2023, even as research has continued to find no causal association. Notably, few adults (4%) say they think this myth is “definitely true,” while a larger share (33%) say it is “definitely false.”

Eight in ten adults (81%) in the June survey said they were very or somewhat confident in the safety of these vaccines for children, and 84% of parents said the same in the KFF/The Washington Post Survey of Parents conducted in summer 2025. 

How is this reflected in online conversations?

Claims about vaccines and autism, both perpetuating and debunking a connection, remain a prominent part of online vaccine discourse. KFF’s monitoring of social media found that on August 11, the day after the EO was signed, the number of posts, reposts, and comments that mentioned keywords relating to both vaccines and autism reached their highest volume of 2026 thus far, across X, Reddit, and YouTube. On that day, more than 38,000 posts, reposts, and comments contained keywords for both of these topics, compared to a daily average of about 5,800 this year as of August 21. While it is not possible to attribute the spike in posts directly to the EO, a share of posts mentioning both vaccines and autism also included a direct reference to the order.

While many posts sought to refute a connection between autism and vaccines, some posts with high engagement repeated false claims about the alleged connection. Some of these posts included video clips of false comments made by Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., including claims that “none of the vaccines have ever been tested for autism.” Another claimed that Kennedy had “debunked” existing studies about a possible connection.

What does the research on MMR vaccine safety say?

Several studies over the last decade have found no evidence of a causal association between MMR vaccines and autism. Most recently, a retrospective cohort study of more than 2.5 million children published last month found no association between the first dose of MMR vaccination, typically given between 11.5 and 24 months, and autism diagnosis. The new study did not specifically examine the second dose, which is usually given between ages 4 and 6.

There have been no deaths linked to combined MMR vaccination in healthy people, which had been administered more than 800 million times as of 2021.

Why This Matters

Beyond directly suggesting a causal link between vaccines and autism where none has been proven, official calls for more research into a question the scientific consensus already regards as settled introduce an unwarranted perception of uncertainty. These calls may incorrectly imply that existing evidence is inconclusive or that the question remains genuinely open, a framing that research shows can undermine public trust when applied to questions that are already settled. KFF polling from May showed that among parents who reported skipping or delaying vaccines for their children, a large share expressed mixed and uncertain beliefs across several common vaccine myths, underscoring the connection between confusion, uncertainty and these parents’ behavior.


What We’re Watching

False Claims About COVID Vaccines and Miscarriage Follow Release of Fauci Texts

Claims that COVID-19 vaccines during pregnancy pose a serious risk of miscarriage resurfaced earlier this month after Republican Senators released text messages from former NIAID Director Anthony Fauci’s government cell phone. In one message, from January 2021, Fauci noted the theoretical concern that fever after a second dose of the vaccine could be associated with miscarriage. The message was sent several months before the Centers for Disease Control and Prevention (CDC) completed its analysis of vaccine safety during pregnancy. The agency did not recommend the vaccine during pregnancy until August 2021, after its analysis showed no increased risk of miscarriage.

KFF media monitoring found multiple highly engaged-with social media posts amplifying misleading claims, suggesting that concerns about miscarriage were a prominent part of the online response to the released messages. Some posts, including those shared by Senator Rand Paul, repeated the false claim that the vaccine was proven to cause miscarriage in up to 82% of pregnancies, a claim that relies on a misreading of a 2021 study whose actual finding of a 12.6% miscarriage rate was in line with prevalence generally.

Research does not support an elevated risk of miscarriage following COVID-19 vaccination. On the other hand, COVID infection during pregnancy has been shown to be associated with higher risk of both severe illness and pregnancy loss. Major medical organizations, including the American College of Gynecologists and Obstetricians (ACOG), continue to recommend vaccination during pregnancy because of the vaccines’ known safety and benefits to both the pregnant person and for infants who are too young to get vaccinated.

Why This Matters: False claims can recur in public discourse even after being debunked repeatedly over the course of several years. The claim of an 82% miscarriage rate has circulated since 2021 and been repeatedly corrected, but a fresh news hook, like the release of Fauci’s text messages, can reintroduce it to audiences who are already uncertain. A May 2022 KFF poll found that about six in ten (58%) women who were pregnant or trying to become pregnant were not confident in the vaccines’ safety during pregnancy. Widespread uncertainty has continued as official federal guidance has shifted and false claims about these vaccines’ safety have been repeated.

State Attorneys General Investigate Alleged Financial Motivations for Vaccine Recommendations

Recent investigations announced by attorneys general across multiple states are examining whether financial interests may have influenced vaccine recommendations, potentially reinforcing public skepticism about the motives of public health officials and medical organizations.

In August, Florida, Louisiana and West Virginia announced an investigation into former NIAID Director Anthony Fauci, citing journal entries released by Senator Rand Paul that detailed his communications during the pandemic. The investigation will examine Fauci’s financial awards, professional opportunities, and communications related to COVID-19 vaccines. Florida Attorney General James Uthmeier said that his state will also examine whether Fauci personally benefited from guidance he issued during the pandemic. Fauci has not been charged with a crime. The investigations follow a Senate committee voting to hold Fauci in contempt of Congress after he repeatedly invoked his Fifth Amendment right to not testify at a hearing last month.

Texas Attorney General Ken Paxton began a separate investigation into financial incentives for childhood vaccines in January, initially examining medical providers, insurers, vaccine manufacturers and other entities. It has since expanded to focus on the American Academy of Pediatrics (AAP), including whether financial relationships with pharmaceutical companies influenced its vaccine recommendations. The investigation comes as a growing number of states have moved away from following federal vaccine recommendations; as of August, most states (30, including DC) rely on non-federal sources for at least some childhood vaccine recommendations, with most following AAP guidance.

Similar claims about financial incentives have circulated for months, including from HHS Secretary Robert F. Kennedy Jr., who alleged last summer that doctors were improperly being “paid to vaccinate.” Incentive programs for providers do exist, but they are legal, not offered by vaccine manufacturers, and based on dozens of metrics beyond vaccination.

Why This Matters: Repeatedly framing vaccine recommendations as potentially driven by financial incentives could reinforce perceptions that health institutions prioritize financial interests over patient health, particularly as officials question longstanding vaccine recommendations. KFF’s April 2026 Tracking Poll on Health Information and Trust found that fewer than half of adults expressed confidence in federal health agencies like the CDC and Food and Drug Administration (FDA) to act independently without interference from outside interests.

About The Health Information and Trust Initiative: the Health Information and Trust Initiative is a KFF program aimed at tracking health misinformation in the U.S., analyzing its impact on the American people, and mobilizing media to address the problem. Our goal is to be of service to everyone working on health misinformation, strengthen efforts to counter misinformation, and build trust. 


View all KFF Monitors

The Monitor is a report from KFF’s Health Information and Trust initiative that focuses on recent developments in health information. It’s free and published twice a month.

Sign up to receive KFF Monitor
email updates


Support for the Health Information and Trust initiative is provided by the Robert Wood Johnson Foundation (RWJF). The views expressed do not necessarily reflect the views of RWJF and KFF maintains full editorial control over all of its policy analysis, polling, and journalism activities. The data shared in the Monitor is sourced through media monitoring research conducted by KFF.

Medicaid Coverage for Women

Published: Aug 26, 2026

Medicaid, the nation’s health coverage program for people with low incomes, provides more than 39 million women across the nation with health and long-term care coverage. Women comprise the majority of the adult Medicaid population and the program offers coverage of a wide range of primary, preventive, specialty, and long-term care services that are important to women across their lifespans. Given the importance of the program for women and their families, changes to the program, such as the 2025 federal policy changes to Medicaid and the enactment of new work requirements for the Medicaid expansion population, will have significant implications for low-income women’s access to coverage and care. This data note presents key data points describing the current state of the Medicaid program as it affects women.  

Who is Eligible for Coverage?

In 2023 adult women comprised 37% of the overall Medicaid population and the majority of adults on the program (Figure 1).1 Prior to the 2010 Affordable Care Act (ACA), women were more likely to qualify for Medicaid than men because of their lower incomes and because they were more likely to belong to one of Medicaid’s categories of eligibility for adults: pregnant, parent of a dependent child, senior, or person with a disability. The ACA added a new Medicaid eligibility category by extending Medicaid eligibility to nearly all adults under age 65 with incomes up to 138% of the federal poverty level (FPL), though women are still more likely than men to be covered by Medicaid.

Pie chart showing age and gender breakdown of individuals enrolled in Medicaid in 2023. Overall, adult women 19 and older make up the majority of the adult Medicaid population, and women of reproductive age (ages 19 to 49) make up 24% of the whole Medicaid population.
  • As of May 2026, 40 states and DC have opted to expand eligibility for Medicaid under the ACA, which allows women and men with low incomes below 138% FPL to qualify regardless of their pregnancy, parenting or disability status.  
  • In the 10 states that have not expanded Medicaid under the ACA, adults only qualify if they meet income criteria AND belong to one of the previously mentioned categorical eligibility groups. While there are federal eligibility minimums, states have the option to expand eligibility levels for each group up to certain limits. As a result, income eligibility criteria vary for different groups of beneficiaries within as well as between states.
  • In the states that have not adopted the ACA Medicaid expansion, approximately 576,000 women ages 19 to 64 with incomes below the federal poverty level and who are uninsured fall into a “coverage gap.” This is because they earn too much money to qualify for Medicaid in their state but not enough to qualify for assistance purchasing a private policy through their state’s ACA Marketplace, which is available for individuals with incomes between 100% FPL and 400% FPL.
  • H.R. 1, the 2025 budget reconciliation law, has made significant changes to the Medicaid program. For the first time, eligibility for adults in the ACA Medicaid Expansion group will be conditioned on meeting work requirements, starting January 1, 2027. Prior KFF research has shown that most adult women covered by Medicaid meet work requirements or could qualify for one of the law’s exemptions (including being a parent of a child under age 14), but they are at risk of losing coverage because of the administrative burdens related to reporting requirements. In 2023, approximately 40% of adult women enrolled in Medicaid were enrolled via the ACA expansion pathway.2 The Congressional Budget Office (CBO) estimates that these requirements will reduce federal Medicaid spending by $326 billion over the next 10 years but will also increase the number of uninsured by 5.3 million in 2034.

Profile of Women Under 65 Covered by Medicaid

Medicaid covers a diverse population of women who face many social, economic, and health challenges that affect their ability to receive timely and high-quality health care.  

  • In 2024, Medicaid covered 18% of adult women ages 19 to 64 in the United States, but coverage rates were higher among certain groups, such as women of color, single mothers, low-income women, and women who have not completed a high school education (Figure 2).  
Bar chart showing the share of women ages 19 to 64 who are covered by Medicaid across various selected subgroups. Higher shares of women with lower incomes, single moms, and women of color are covered by Medicaid compared to the national average.
  • Differences in Medicaid eligibility levels and poverty rates across the states translate into vastly different Medicaid coverage rates for women across states, from a low of 9% in Utah and Texas to 32% in New Mexico (Figure 3).  
This map of the United States shows that Medicaid coverage among women ages 19 to 64 varies considerably across states. Coverage is highest in many states in the Northeast, Midwest, and West, while lower coverage is more common across parts of the South and Mountain West.

Adult women of reproductive age (19 to 49) comprise a quarter (24%) of the Medicaid population (Figure 1). Medicaid covers a wide range of reproductive health care services, including family planning, and pregnancy-related care including prenatal services, childbirth, and postpartum care—all without cost-sharing. Medicaid coverage of abortion services, however, is very limited under federal law and in most states.  

Family Planning 

Federal law requires state Medicaid programs to offer family planning benefits, but states determine the specific services and supplies for those who qualify through pre-ACA pathways. For the ACA expansion populations, the ACA requires states to cover all FDA approved, granted, and cleared  contraceptive methods, counseling on STIs and HIV, and screening for breast and cervical cancers. Research has found that most states have aligned their benefits and cover these services across all eligibility groups.  

  • The federal government pays 90% of costs for family planning services, a higher federal matching rate than for other services (typically between 50% and 78%). Women covered by Medicaid cannot be charged any out-of-pocket costs for family planning services. 
  • Federal law states that Medicaid beneficiaries have “free choice of provider,” which allows them to seek care from any qualified participating provider that offers the services. However, contrary to longstanding interpretation of the free choice of provider clause, a 2025 Supreme Court ruling, Medina v. Planned Parenthood South Atlantic, allows state Medicaid programs to disqualify clinics from participating in their networks if they offer abortion care in addition to other medical services. As of June 2026, at least seven states (AR, MO, MS, NE, OK, SC, and TX) have bans on Planned Parenthood’s participation in Medicaid, and several other states have proposed similar policies. Nationally, one in ten (10%) reproductive age women covered by Medicaid who received family planning services got their care at a Planned Parenthood clinic in 2023.
  • In addition to the Medina ruling, H.R.1 established a one-year ban on federal Medicaid reimbursements to Planned Parenthood in all states and some other reproductive health providers that provide abortion services. The policy was in effect from July 2025 to July 2026. While this rule expired, future legislation could be enacted by Congress to reinstate this funding ban.
  • Over half of states currently operate limited scope Medicaid family planning programs, which extend access to family planning services to uninsured women who do not qualify for full Medicaid coverage (often because their incomes exceed the Medicaid income thresholds).  

Maternity Care  

Medicaid is the largest single payer of pregnancy-related services, financing 40% of all U.S. births in 2024. In three states Medicaid covers more than 50% of all births. By federal law, all states provide Medicaid coverage without cost sharing for pregnancy-related services to pregnant people with incomes up to 138% of the federal poverty level (FPL), but many states extend eligibility to those at higher income levels. 

  • Similar to family planning, there is no federal definition of what services states must cover under their traditional Medicaid programs for pregnant women beyond inpatient and outpatient hospital care, but states that have expanded Medicaid eligibility must cover all preventive services recommended by the United States Preventive Services Task Force (USPSTF) to individuals who qualify through this pathway, which includes a broad range of pregnancy-related preventive services. Overall, most states cover a broad range of maternity care services, including prenatal screenings, folic acid supplements, and breastfeeding supports. States may not charge cost-sharing for any pregnancy-related services.
  • Historically, Medicaid coverage for pregnant people ended after 60 days. Due in part to the high rates of maternal mortality and morbidity in the United States and the disproportionately high rates of poor maternal outcomes experienced by Black and Native American pregnant people, there was a growing interest in expanding postpartum coverage beyond the 60 days. The federal American Rescue Act of 2021 gave states the option to extend postpartum coverage to pregnant people to a full year. To date, all states, with the exception of Arkansas, have extended postpartum coverage to 12 months.   
  • In the 10 states that have not expanded Medicaid coverage under the ACA, many women lose Medicaid eligibly after the postpartum period. This is because the income eligibility for pregnancy-related care is typically considerably higher than that offered to parents of dependent children. Eligibility levels for parents in the states that have not expanded Medicaid range from 15% FPL in Texas to 105% FPL in Tennessee (Figure 4). In the states that have expanded Medicaid eligibility, most women with Medicaid financed births are able to remain enrolled in the program and have continuous coverage beyond the postpartum period. 
Column chart showing that Medicaid income eligibility limits for parents are much lower in states that have not expanded Medicaid compared to states that have expanded Medicaid.

Abortion  

While the 2022 Dobbs decision overturning Roe v. Wade eliminated federal protections and allowed states to ban or severely restrict the provision of abortion, abortion remains legal and available in many states. However, the federal Hyde Amendment prohibits federal spending on abortions in all states, except when the pregnancy is a result of rape or incest, or when it jeopardizes the life of the pregnant person (Figure 5). States may use their own unmatched funds to cover abortions in other circumstances. As of July 2026, 29 states (including the 13 states where abortion provision is currently banned) and DC follow Hyde restrictions and 21 states cover abortions for Medicaid beneficiaries that are considered to be “medically necessary” and pay for these using only state funds. Nearly half of women of reproductive age with Medicaid coverage live in a state that follows Hyde amendment standards or currently bans the provision of abortion. In cases when Medicaid finances abortions for Medicaid enrollees, reimbursement rates tend to be low and often do not cover the full cost of the procedure.

This map shows that Medicaid coverage for abortion is very limited across the U.S. The majority of states, including the 13 states where abortion provision is banned, follow the federal Hyde restrictions and only cover abortions when the pregnant person's life in danger or the pregnancy is the result of rape/incest. Twenty-one states use their own funds to pay for abortions for Medicaid enrollees.

As women age, their health needs generally shift from reproductive care to greater need for screening and management of chronic diseases, mental health care, and disability care (although many women in their reproductive years also have these health needs).  

Mental Health  

  • In 2024, Medicaid covered over one in four (27%) adult women with any mental illness and 31% of adult women with a serious mental illness. 
  • Medicaid’s behavioral health benefits include acute care services, long-term services and supports to enable people with chronic illness to receive community-based care. In addition, states with Medicaid expansion programs are required to cover 10 essential health benefits, which include mental health and substance use disorder services, including behavioral health treatment.  

Breast and Cervical Cancers 

  • Under the Breast and Cervical Cancer Prevention and Treatment Act, states may extend Medicaid coverage for cancer treatment to uninsured women diagnosed with breast or cervical cancer through a federal screening program and receive a federal match for those services. In 2023, 44,000 women were enrolled in Medicaid through the Breast and Cervical Cancer Program.  
  • Preventive services for breast and cervical cancers are required benefits in ACA Medicaid Expansion programs. States are required to cover mammograms and pap tests, genetic (BRCA) screening for high-risk women, and breast cancer preventive medication for high-risk women. Most states cover the screening tests for all beneficiaries. However, coverage for other services such as such as colposcopy following an abnormal pap result (which will be a required as a covered services under the HRSA Women’s Preventive Services  Guidelines effective January 2027) and genetic screening for women at higher risk of breast cancer is more uneven across state eligibility pathways.  

Disability, Aging and Long-Term Care

Women with Disabilities  

  • Medicaid covers four in ten (41%) nonelderly women who have a broad range of physical and mental disabilities, including physical impairments, severe mental illnesses, and specific conditions such as muscular dystrophy, cystic fibrosis, and HIV/AIDS (Figure 6).3 In addition, Medicaid also covers some nonelderly women who separately also qualify for Medicare coverage due to long-term disabilities (discussed below). 
  • Benefits that Medicaid covers include: assistance with medical and supportive services including rehabilitation, transportation, and therapeutic services, which help people with disabilities live independently and are not typically covered by private health insurance plans. Long-term services, including home health care, are another critical health benefit for women with disabilities that has very limited coverage through commercial plans but is covered by Medicaid.  
Pie showing health insurance coverage for women ages 19 to 64 with disabilities in 2024 in the U.S. Medicaid is a major source of coverage for women with disabilities, covering 41%, with another 34% getting coverage through employer-sponsored insurance.

Medicare-Medicaid Enrollees and Long-Term Care 

Medicare provides health coverage to people 65 and older and younger people with long-term disabilities. Medicaid provides coverage to approximately 12 million Medicare beneficiaries (20% of all Medicare beneficiaries) with low incomes and modest assets. These individuals are often referred to as “dually eligible beneficiaries,” and in 2023, women of all ages accounted for 60% of this group (Figure 7). Many of these beneficiaries have extensive and costly health needs.  

  • The majority of dually eligible beneficiaries qualify for full Medicaid benefits and may receive coverage for services that Medicare does not currently cover, such as dental and vision care, and long-term services and supports. Other dually eligible beneficiaries may only receive assistance with their Medicare premiums and/or cost sharing through the Medicare Savings Programs, but not full Medicaid benefits, if they meet an income and asset test. 
Women Account for Six in Ten Medicare Beneficiaries Who Are Enrolled in Both Medicare and Medicaid (Donut Chart)
  • Medicaid covers a continuum of long-term services and supports ranging from home care (HCBS) that allow persons to live independently in their own homes or in other community settings to institutional care provided in nursing facilities and intermediate care facilities for individuals with intellectual disabilities. In 2023, HCBS represented 64% of total Medicaid expenditures on long-term care (LTC).  
  • Since women are more likely to live longer and experience higher rates of chronic illness and disability than men, they are more likely to require long-term services in their lifetime. Approximately two-thirds of nursing home residents (61%) and people receiving home health care (60%) are women. Medicaid coverage provides access to these long-term services, which would otherwise be unaffordable for women with fixed incomes (in 2025, nursing home care averaged more than $114,975 annually for a semi-private room).  

Compared to their uninsured counterparts, women with Medicaid experience fewer barriers to care and on several measures have utilization rates comparable to low-income women with private insurance.  

  • Women covered by Medicaid use primary and preventive health services, such as pap smears and mammograms, at rates comparable to women with private insurance and at higher rates than uninsured women (Figure 8).  
These grouped columns show that among lower-income women, those with Medicaid coverage are just as likely as women with private coverage to have a regular doctor and to receive Pap or HPV testing, and they report relatively high rates of mammograms and colon cancer screening. Uninsured women generally report lower rates of preventive care.
  • Women with Medicaid coverage are less likely than uninsured women to experience cost barriers. Compared to low-income women with private insurance, women on Medicaid were less likely to report that they delayed or went without care due to cost, likely attributable to the fact that Medicaid does not charge deductibles, rarely charges premiums and has only nominal cost-sharing. Affordability, however, is still a problem for some women in the program because they are typically low-income and have to pay out of pocket costs in states that impose caps on the number of covered visits or prescriptions or charge copayments for prescription drugs (for non-pregnant adults). Three in 10 low-income women on Medicaid report that they had not filled a prescription (31%) in the past year because of the cost (Figure 9).  
Grouped columns showing that among women with lower incomes ages 18 to 64, those with Medicaid coverage are less likely than uninsured women, and in some cases women with private coverage, to report delaying care, skipping recommended tests or treatments, or not filling prescriptions because of cost.
This table shows that Medicaid coverage among women ages 19 to 64 varies across racial and ethnic groups, education levels, family types, and income levels. Medicaid coverage is more common among women with lower incomes, those with less education, and single parents, as well as among American Indian and Alaska Native and Black women.
  1. KFF analysis of the T-MSIS Research Identifiable Files, 2023 (Preliminary) ↩︎
  2. KFF analysis of the T-MSIS Research Identifiable Files, 2023 (Preliminary) ↩︎
  3. KFF estimate based on the 2024 American Community Survey, 1-year estimates ↩︎

Availability of Rural Hospitals Providing Inpatient Maternity Care in Medicaid

Published: Aug 26, 2026

In recent years, concerns about access to maternity care in rural areas have grown as hundreds of rural hospitals have closed their obstetrics units. In 2023, approximately half of rural hospitals offered obstetrics services, and almost half of rural counties did not have a hospital offering obstetrics services. A lack of access to maternity care can lead to negative health outcomes, such as low birthweight and premature births, and increased maternal mortality. According to a Government Accountability Office study, difficulty recruiting and retaining providers and low Medicaid reimbursement rates are some of the biggest challenges to providing obstetric services in rural areas. Medicaid is a major payer of obstetrics care in rural communities, covering almost 1 in 4 rural women of reproductive age and financing nearly half of all births in rural communities.

Existing concerns for hospital-based rural maternity care access are expected to grow due to cuts to Medicaid in the 2025 reconciliation law that are projected to reduce spending in rural areas through changes to hospital supplemental payments and reduced Medicaid enrollment. Although increasing obstetric payments to hospitals has been a priority for many states over the past decade, changes from the reconciliation law could result in reduced Medicaid revenues for hospital services, including for rural hospitals that already have lower financial margins. While the temporary rural health fund included in the law allocates $50 billion over ten years to reduce the impact of the Medicaid cuts in rural areas, not all of it is directed to rural hospitals and, overall, it is not likely to offset the longer-term impacts of the cuts.  

Considering the existing challenges to hospital-based maternity care in rural areas and the potential for worsening trends, this brief analyzes the availability of hospitals providing inpatient maternity care in rural areas for Medicaid enrollees and illustrates how access to these services could be affected if additional rural hospitals were to close or eliminate those services. For the purposes of this data note, hospitals offering inpatient maternity care are defined as those that delivered 10 or more births in the year (see Methods).

Over 1 in 3 hospitals providing inpatient maternity care to Medicaid enrollees are in rural areas.

In 2023, 943 rural hospitals provided inpatient maternity care to Medicaid enrollees, constituting 39% of hospitals nationally providing inpatient maternity care to Medicaid enrollees. Rural hospitals that were adjacent to urban areas (rural adjacent) accounted for 778 (32%) hospitals, and the most rural hospitals (those not adjacent to urban areas, remote rural) accounted for 165 (7%) hospitals (Figure 1).

Over One in Three Hospitals Providing Inpatient Maternity Care to Medicaid Enrollees are in Rural Areas (Small multiple donut chart)

Rural hospitals providing inpatient maternity care to Medicaid enrollees are typically located more than 40 minutes from the closest in-state hospital providing inpatient maternity care.

If a rural hospital closes, one measure of the effect on Medicaid enrollees is the amount of time it would take to drive to the nearest in-state hospital. The typical drive time between hospitals providing inpatient maternity care to Medicaid enrollees and their closest in-state neighbors is 43 minutes for rural hospitals compared with 13 minutes for urban hospitals (Figure 2). For 1 in 4 of these rural hospitals, the nearest in-state hospital that provided inpatient maternity care is at least one hour away (Figure 2). Distance to the nearest in-state hospital was calculated because most Medicaid enrollees obtain medical services within their state of residence, and though states have special processes for enrolling and paying out-of-state hospitals, seeing providers across state lines is challenging for enrollees (see Methods). The analysis uses driving time (in minutes) as a measure of distance between two hospitals because it accounts for traffic patterns between rural and urban areas, but results are similar when using other measures of distance (Appendix Figure 1).

Rural Hospitals Providing Inpatient Maternity Care to Medicaid Enrollees are Typically Located More Than 40 minutes from the Closest In-State Hospital Providing Inpatient Maternity  Care (Dot Plot)

Typical drive times from rural hospitals providing inpatient maternity care to Medicaid enrollees to the closest in-state hospital providing inpatient maternity care vary by state.

In 14 states, the typical drive time from rural hospitals providing inpatient maternity care to Medicaid enrollees to their nearest in-state neighbor is one hour or more (Figure 3).The top three states with the longest typical driving times are Alaska, Nevada, and North Dakota. The states with the shortest drive times between their rural hospitals and another hospital providing inpatient maternity care to Medicaid enrollees are New Jersey, Louisiana, and Ohio.

Typical Drive Times From Rural Hospitals Providing Inpatient Maternity Care to Medicaid Enrollees To The Closest In-State Hospital Providing Inpatient Maternity Care Vary by State (Choropleth map)

Patrick Drake, an independent consultant, contributed to the analysis of driving time data.

Appendix

Comparison of Different Hospital Distance Measures (Dot Plot)
Number of Hospitals Providing Inpatient Maternity Care to Medicaid Enrollees by State and Rurality, 2023 (Table)

Methods

Data: This analysis uses data available from the 2023 Preliminary T-MSIS Research Identifiable Demographic-Eligibility and Claims Files. The Inpatient (IP) Header File was used to identify hospitals providing inpatient maternity care to Medicaid enrollees.

State Inclusion Criteria: To assess the usability of states’ data, four relevant quality assessments from the DQ Atlas were examined for IP claims file and billing provider completeness. KFF also evaluated usability based on the percentage of hospitals that merged with two external data sources used in the analysis for hospital addresses (CMS Hospital Enrollments and AHA Annual Survey data). The billing provider National Provider Identifier (NPI) is the primary hospital identifier in the claims data for this analysis (see more details under “Identifying Hospitals”). Below are the states that were excluded according to each criterion:

  • DQ Atlas Claims Volume – IP: No states excluded
  • DQ Atlas Service Users – IP: No states excluded
  • DQ Atlas Billing Provider NPI – IP: Georgia was deemed “unusable” for this assessment and excluded. Approximately 81% of its IP Header claims were missing a billing provider NPI.
  • DQ Atlas Billing Provider Type, Specialty, and Taxonomy – IP: No states excluded
  • KFF state-level merge rates to CMS Hospital Enrollments and AHA Annual Survey data: Rhode Island was excluded. Approximately 44% of its IP Header claims were unable to merge onto either the CMS Hospital Enrollments or the AHA Annual Survey data, and thus hospital address could not be determined (other states, except Georgia, had 15% or less of their claims unable to merge).

Identifying Inpatient Maternity Care: A hospital was identified as providing “inpatient maternity care” when it provided 10 or more live births to Medicaid enrollees, following other studies on obstetric care access in rural areas. Diagnosis and procedure codes in the T-MSIS inpatient header claims files were used to identify live birth codes from the Office of Population Affairs’ published code lists for the Contraceptive Care Measures that are endorsed by CMS’ consensus-based entity. A list of diagnosis and procedure codes is available upon request.

Identifying Hospitals: Hospitals were identified in the claims data using billing provider NPI. According to DQ Atlas methodology, the billing provider in the IP file primarily represents the hospital where the inpatient care occurred.

Hospital address information: This analysis used data available from the 2025 CMS Hospital Enrollments (accessed in November 2025) and data available from FY2021 AHA Annual Survey (accessed in February 2023) to identify hospital addresses. The CMS Hospital Enrollments data set provides monthly enrollment information for all hospitals currently enrolled in Medicare and the AHA Annual Survey provides data from an annual survey of all hospitals in the U.S. and its associated areas. KFF used both sources to account for hospitals that may have closed between 2023 and 2025 or opened between 2021 and 2023 (2023 was the most current year of T-MSIS data at the time of analysis).

The analysis used these external sources rather than the T-MSIS Annual Provider File (APR) because of concerns regarding data quality in the APR file. Technical documentation for the APR suggests that users may want to use the NPI to link to external data sources to obtain additional provider information, and other researchers have found provider legal name and address in the APR to be inconsistent.

Hospital exclusion criteria: Below is a list of criteria used to identify hospitals providing inpatient maternity care to Medicaid enrollees in the analysis. The number of unique NPIs and the number of IP Header claims that were kept after each step are reported.

Only hospitals identified as a general acute care hospital using National Plan and Provider Enumeration System (NPPES) taxonomy codes were included in the analysis because they are accessible to all Medicaid enrollees and treat a range of health care conditions. Hospital types that were excluded from the analysis include: chronic disease hospitals, long-term care hospitals, religious nonmedical health care institutions, psychiatric hospitals, rehabilitation hospitals and military hospitals.

Exclusion Criteria# of Unique Billing Provider NPIs Remaining# of IP Header Claims
Start: All unique billing provider NPIs/header claims in the IP file10,973 (100%)12,267,627 (100%)
Claims without a live birth diagnosis or procedure code3,132 (7,841 dropped)1,715,496 (10,552,131 dropped)
Submitting state for the claim is GA or RI (see “State Inclusion Criteria”)2,995 (137 dropped)1,648,650 (66,846 dropped)
Billing provider NPI is associated with a RI, GA or PR zip code2,953 (42 dropped)1,646,590 (2,060 dropped)
Billing provider NPI is missing or less than 10 digits2,951 (2 dropped)1,644,384 (2,206 dropped)
Billing provider taxonomy code is not a general acute care hospital or is missing2,675 (276 dropped)1,626,606 (17,778 dropped)
Did not merge onto CMS Hospital Enrollments or AHA Annual Survey data2,596 (79 dropped)1,600,273 (26,333 dropped)
Claim is not for a Medicaid eligible enrollee (CHIP_CD = 1 or, if missing, ELGBLTY_GRP_CD = 1-60 or 69-75) or with a Medicaid claim type code (CLM_TYPE_CD = 1 or 3).2,595 (1 dropped)1,466,715 (133,558 dropped)
NPIs that correspond to the same hospital address/coordinates/CCN2,537 (58 dropped)1,466,715 (claims not dropped since they represent the same hospital)
NPIs that had fewer than 10 births2,439 (98 dropped)1,419,113 (dropped)
End: Final unique billing provider NPIs/header claims in the IP file included in the analysis2,439 (22%)1,419,113 (12%)
 

Defining Rural Hospitals: To define hospital rurality, this analysis uses 2020 USDA Rural-Urban Commuting Area (RUCA) Codes at the hospital zip code level, which is the main geographic identifier included in either the CMS Hospital Enrollments or AHA Annual Survey data. This analysis categorized hospitals as urban, rural adjacent, and remote rural as follows:

Urban

  • 1: Metropolitan core: primary flow is within a metro urban area (UA)
  • 2: Metropolitan high commuting: primary flow is 30% or more to a metro UA
  • 3: Metropolitan low commuting: primary flow is 10% to 30% to a metro UA

Rural adjacent

  • 4: Micropolitan core: primary flow is within an urban area of 10,000 to 49,999 people (micro UA)
  • 5: Micropolitan high commuting: primary flow is 30% or more to a micro UA
  • 6: Micropolitan low commuting: primary flow is 10% to 30% to a micro UA
  • 7: Small town core: primary flow is within an urban area of 9,999 or fewer people (small town UA)
  • 8: Small town high commuting: primary flow is 30% or more to a small town UA
  • 9: Small town low commuting: primary flow is 10% to 30% to a small town UA

Remote rural

  • 10: Rural area: primary flow is to a tract outside an UA

Calculating Distance Measures Between Hospitals: Hospital addresses were geocoded using data from OpenStreetMap (OSM). Hospital names and addresses were matched to OSM features, and corresponding latitude and longitude coordinates were extracted. Thirty-five hospitals (1%) were not matched to coordinates using OSM and were manually geocoded using Google Maps searches of hospital names and addresses.

Hospital distances were calculated between hospitals within the same state because most Medicaid enrollees obtain medical services within their state of residence, and because states have special processes for enrolling and paying out-of-state hospitals. Only 7% of hospitals in this analysis have the nearest hospital in another state, and results were not meaningfully changed by this decision.

To identify the nearest hospital within a state, straight-line distances were calculated using the Haversine formula (“as the crow flies”) for each hospital pair in a state, which is consistent with other hospital distance analyses. The hospital with the shortest “as the crow flies” distance was chosen as the nearest hospital. Travel mileage and times to the nearest hospital were then computed using the OSM road network via the Open Source Routing Machine (OSRM) public API. Routing followed drivable paths and incorporated road characteristics from OSM (see OSM Routing documentation).

The Status of Abortion-related State Ballot Initiatives Since Dobbs

Last updated on August 21, 2026

Since the Supreme Court’s Dobbs decision, overturning Roe v. Wade, voters in 17 states have weighed in on ballot measures regarding abortion– some more than once. In November 2026, voters in Idaho, Missouri, Nevada, and Virginia will weigh in on abortion measures that could change the legal status of abortion in their state. In addition, a measure in Colorado is in the process of collecting signatures.  

In 2024, 10 states voted on abortion measures that sought to affirm that the state constitution protects the right to abortion. Nebraska voted on two measures: one seeking to protect abortion and the other seeking to ban abortion after the first trimester. Measures protecting abortion rights succeeded in 7 states — Arizona, Colorado, Maryland, Missouri, Montana, Nevada, and New York — and failed in 3 — Florida, Nebraska, and South Dakota. Voters passed a measure amending the Nebraska state constitution prohibiting abortions after the first trimester.  

Prior to the 2024 election, the side favoring access to abortion prevailed in every state that voted on abortion-related ballot measures. In 2022 and 2023, California, Michigan, Ohio, and Vermont voters passed measures amending the state constitution to protect the right to abortion. Measures seeking to curtail the right to abortion in Kentucky, Kansas, and Montana failed.  

There are two ways a measure may be placed on the ballot: through citizen initiative or legislative referral. 

  • Legislatively-referred  measures are introduced and approved by lawmakers before they appear on the ballot for citizens to vote on. 
  • Citizen-initiated  measures are written by citizen groups and are placed on the ballot if they receive enough signatures.  

Not all states allow for citizen-initiated ballot measures. For more background information on abortion related ballot initiatives, please see our brief Addressing Abortion Access through State Ballot Initiatives

For more information on confirmed and potential abortion-related ballot measures in the 2026 election, please see our brief Abortion on the 2026 Ballot: The Evolving Landscape of State Abortion Initiatives

Status of Abortion-Related Ballot Measures Since Dobbs, as of August 21, 2026 (Table)

Kindergarten Routine Vaccination Rates Continue to Decline

Published: Aug 21, 2026

As measles cases rise across the U.S., children’s routine vaccination rates continue to decline while exemptions from school vaccination requirements, particularly non-medical exemptions, have increased. These trends began during the COVID-19 pandemic and have continued (Figure 1), signaling a shift in attitudes toward childhood vaccinations. This period has seen widespread vaccine misinformation and more skepticism among the public about the safety and effectiveness of measles vaccines as well as a decline in trust of health authorities in general and increasingly partisan views on vaccine requirements. Department of Health and Human Services (HHS) Secretary Kennedy and the Trump administration have also made significant changes to federal vaccine policy, including several attempts to change childhood vaccine recommendations and dropping Medicaid vaccine reporting requirements. Due to recent federal actions, most states have announced that they are no longer following federal recommendations as their benchmark for some or all childhood vaccines. As the school year begins, these changes along with changes to school vaccine exemption requirements in some states may increase confusion for families and could further drive down vaccination rates among children. This issue brief provides an update on the latest trends in kindergarten children’s routine vaccination and exemption rates as state and federal vaccination policy continues to evolve.

States Have Experienced Declines in Vaccination Rates and Increases in Exemption Rates in Recent Years (Stacked column chart)

The share of kindergarten children up to date on their vaccinations continues to decline. Data collected and aggregated annually by the CDC from state and local immunization programs found that 92.4% of kindergarteners had been vaccinated against measles, mumps, rubella (MMR) and polio and 92.0% against DTaP (diphtheria, tetanus, and acellular pertussis) for the 2025-2026 school year. This is down from 95% across all three vaccines for the 2019-2020 (pre-pandemic) school year and below coverage levels of the past decade. MMR vaccination rates also fall below the Healthy People 2030 “target” rate of 95%, the level needed to prevent community transmission of measles, leaving approximately 280,000 kindergarteners  unvaccinated and unprotected against a highly contagious and life-threatening virus. While measles has been officially “eliminated” from the U.S. since 2000, measles cases have surged over the past two years. In 2026, the U.S. has reported more cases of measles than in any year since 1991, putting the U.S.’s elimination status at risk. Measles cases have been reported in most states, with South Carolina, Utah, Pennsylvania, Texas, and Virginia seeing the largest outbreaks so far in 2026.

Over three-quarters (39) of states had MMR vaccination rates below the “target” rate of 95% for the 2025-2026 school year (Figure 2). Further, 18 states reported rates below 90% for the 2025-2026 school year. This is compared to only 28 states below 95% and three states below 90% before the pandemic began. In the last year alone, over half of states experienced declines in vaccination rates for MMR, DTaP, polio, and varicella. There is also substantial variation in vaccination rates across states, with MMR coverage rates among kindergarteners for the latest school year ranging from a low of 75.2% in Idaho to a high of 98.9% in West Virginia. There can also be variation in vaccination coverage within states, and, when there are clusters of unvaccinated people within a specific community, the risk of an outbreak is higher.

Over Three-Quarters of States Had MMR Vaccination Coverage Rates For Kindergarteners Below the Healthy People Target of 95% During the 2025-2026 School Year (Choropleth map)

At the same time, the share of kindergarten children with an exemption from one or more required vaccinations increased. The share of children claiming an exemption from one or more vaccinations rose from 2.5% in the 2019-2020 school year to 4.2% in the 2025-2026 school year, the highest national exemption rate to date. Increases in non-medical exemptions accounted for the recent increases; non-medical exemptions increased from 2.2% to 4.0% while medical exemptions declined slightly from 0.3% to 0.2% from 2019-2020 to 2025-2026. While a seemingly small increase in non-medical exemptions, any increases limit the overall share of children able to be vaccinated and make it more difficult to reach vaccination rate goals. Studies have shown that higher exemption rates are associated with lower vaccination coverage rates and increased risk for disease outbreaks.

Almost half (24) of states in the 2025-2026 school year had vaccine exemption rates over 5% (Figure 3). This is up from eight states during the pre-pandemic school year. Exemption rates over 5% make it impossible to reach vaccination coverage rates at or above 95% even if all non-exempt children were vaccinated (rates shown here are for exemptions to one or more vaccines, so potentially achievable coverage rates could vary by vaccine type). In the last year alone, most states experienced an increase in the share of kindergarteners claiming an exemption for one or more vaccines. States and local jurisdictions, not the federal government, set vaccine requirements and exemption criteria for daycare and school entry. As of 2026, all states and DC required children to be vaccinated against certain diseases, including MMR, to attend public schools, though exemptions are allowed in certain circumstances. All states allow a medical exemption, and almost all (46 states including DC) allow for a religious or personal belief exemption (or both). In recent years, some states have pursued changes to reduce or eliminate requirements or expand non-medical exemptions, which could further impact children’s vaccination trends.

Almost Half of States Had More Than 5% of Kindergarteners Claiming A Vaccine Exemption During the 2025-2026 School Year (Choropleth map)

State and Local Policies on School Vaccine Requirements: Overview and Current Status

Published: Aug 21, 2026

Key Points

  • The Constitution gives authority to state and local governments, not the federal government, to set school vaccine requirements and currently all 50 states and DC currently require certain vaccines for school attendance. All jurisdictions require MMR, DTaP, polio, and varicella vaccination for school-age children, while requirements for several other vaccines vary by state. All states allow for exemptions to these requirements.
  • Jurisdictions differ substantially in how they allow parents to claim exemptions from school vaccine requirements. All states permit medical exemptions, while 45 states and DC permit religious and/or personal belief exemptions. States also vary widely in the documentation, review, and other requirements for obtaining an exemption.
  • Due to actions by the Trump administration, which has questioned the safety and effectiveness of vaccines and sought to reduce the number of recommended childhood vaccines, a growing number of states has begun to delink their recommendations from those of the federal government, which may have implications for school vaccine requirements. As of August 2026, 30 states and DC had announced that they would no longer follow Centers for Disease Control and Prevention’s (CDC) Advisory Committee for Immunization Practices (ACIP) recommendations for one or more childhood vaccines, with 27 states delinking from CDC/ACIP recommendations for all childhood vaccines. Because state and local school vaccination policies may be linked to states’ broader childhood vaccine recommendation policies, these moves could have implications for school entry requirements.
  • Recent state policy changes have generally made non-medical exemptions easier to obtain. Since 2025, at least nine states have enacted changes that make non-medical exemptions more permissive, including by reducing documentation or procedural requirements. Research indicates that easier-to-obtain non-medical exemptions are associated with higher exemption rates and, in turn, declining childhood vaccination coverage.

These trends are taking place in the context of falling national childhood vaccination rates since 2019, declines that are entirely attributable to the growth in non-medical exemptions. Higher exemption rates have been associated with increased incidence of diseases such as measles and pertussis, indicating continued outbreaks that place more children at risk for vaccine-preventable diseases in the U.S. are likely. 

Evolution of School Vaccine Requirements

Under the U.S. Constitution, states (and local governments) have the authority to impose immunization requirements, not the federal government (see Box 1). The earliest known school vaccine requirements in the U.S. were put in place by a local government in the 19th century, when Boston enacted a city-wide requirement for smallpox immunization for school entry in 1827. In 1855, Massachusetts enacted the first state-level school vaccine mandate, also for smallpox. As more childhood vaccines were developed and recommended for routine use over time, states began adding additional requirements for diphtheria, tetanus, pertussis, and polio. By 1963, 20 states required at least one vaccine for children to attend school.

Box 1: Legal Powers of States and the Federal Government Relating to Vaccine Requirements

The U.S. Constitution provides certain public health powers to states and to the federal government. The 10th Amendment “police powers” clause grants states the responsibility for enacting laws to promote health, safety and general welfare (such as public health), which has come to be interpreted as including the power to enact vaccine requirements. . The Constitution grants the federal government public health responsibilities relating to inter-state and border disease control, and tax and spending powers that allow the government to direct funds to states for specific purposes such as vaccinations. In addition, the federal government has licensing and regulatory oversight of vaccines through Department of Health and Human Services (HHS) agencies such as the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC).

Over time there have been legal challenges to states’ powers to impose school vaccine requirements, but the federal courts have consistently ruled in favor of states’ powers. For example, in the Jacobson vs. Massachusetts (1905) ruling, the Supreme Court established that states can mandate vaccines for school attendance and impose fines for non-compliance; Zucht vs. King (1922) affirmed that schools can require proof of vaccination prior to entry; and Prince vs. Massachusetts (1944) upheld states power to impose vaccination mandates despite parental objections based on religious beliefs. As recently as 2026, a federal appeals court affirmed New York state’s 2019 repeal of its prior “religious beliefs” exemption for school vaccine mandates that had been enacted after a large measles outbreak in the state, rejecting a challenge to the law brought by Amish parents (Miller vs. McDonald, 2026).”

In the 1960s, the federal government also increased its support to states for vaccinations and broadened its immunization-related policy-making efforts. In 1962, Congress created the Public Health Service Section 317 Immunization Grants Program, which allowed federal funds to be directed to state and local jurisdictions for purchasing vaccines. In 1964, a new specialized expert committee called the Advisory Committee on Immunization Practices (ACIP) was established at the federal level to provide guidance regarding vaccines. ACIP was designated an official federal advisory committee and placed organizationally under the Centers for Disease Control and Prevention (CDC) Director in 1972. The 1960s and 1970s also saw the licensure of new combination measles, mumps and rubella (MMR) vaccines, coinciding with a number of measles outbreaks among children that drew national attention, and  spurred expanded federal and state efforts to strengthen and update vaccination laws (the measles vaccine was added to the federal 317 program in 1965). In the 1970s, large measles outbreaks in Alaska (1976) and Los Angeles, California (1977) led policymakers in those states to enact stricter measles vaccination requirements for school children that resulted in lower measles incidence, demonstrating to policymakers nationwide that enforcement of immunization requirements was possible, acceptable, and effective for most communities. Subsequently, CDC encouraged all states to implement school immunization requirements. 

By 1981, all 50 states and DC had some form of school immunization requirements, and in the 1981-82 school year, vaccination levels in school entrants nationwide had reached 96% or higher for diphtheria-tetanus-pertussis (DTP), polio, and measles vaccines. In 1983, CDC/ACIP published the first general federal recommendations for childhood vaccinations, which were updated in 1989 and eventually merged with the recommended schedule issued by the American Academy of Pediatrics (AAP) in 1995. Throughout the 1990s and 2000s more vaccines were added to the CDC/ACIP recommendations for children and adolescents, including Hepatitis A, Hepatitis B, Haemophilus influenzae type b (Hib), pneumococcal, rotavirus, varicella, human papillomavirus (HPV), and meningococcal vaccines. Over time, states have integrated many of these vaccines into their school immunization policies as well, though the specific set of required vaccines varies across states, as described below.

Current state policies on school vaccination requirements

As shown in Figure 1, all 50 states and DC require MMR, DTaP, polio, and varicella vaccines for school-age children. Forty-nine states and DC also require Hepatitis B (Alabama is the exception), with three of those states requiring Hepatitis B for childcare settings only (Maine, Montana, South Dakota). Thirty-five states require meningococcal vaccines for school-age children, while 27 states require Hepatitis A. Just four jurisdictions require HPV vaccines for school-age children (DC, Hawaii, Rhode Island, and Virginia).

Figure 1

State Exemption Policies for School Vaccine Requirements

While all states allow for individual exemptions to state school vaccination requirements, the extent of these exemptions vary. They fall into two general categories: “medical” (exemptions based on medical contraindications) and “nonmedical” (exemptions based on religious beliefs or other personal/philosophical beliefs). Currently, all states allow for medical exemptions, while 45 states and DC allow for religious and/or personal belief exemptions (the exceptions are California, Connecticut, Maine, New York, and West Virginia). Of the jurisdictions allowing non-medical exemptions (see Figure 2):

  • 30 states allow religious exemptions only
  • 15 states allow religious and personal belief exemptions
  • 1 state (Minnesota) allows personal belief exemptions only
Figure 2

States also vary in how difficult it is to obtain an exemption and in their oversight of exemptions. All states require some form of documentation from a health care professional to grant a medical exemption, though how rigorous the process is differs across states. Likewise, in states that allow for nonmedical exemptions, documentation and approval processes can vary in their rigor and requirements. For example:

  • In California, physicians issuing medical exemptions must use a centralized system, all exemption requests are reviewed by the state’s health department that has the authority to invalidate inappropriate requests, and justifications must adhere to standards for medical contraindications (previously, the state linked its standards for medical exemptions to CDC/ACIP recommendations, but as of 2025 uses AAP criteria instead). In New York, review and enforcement for exemption requests is the responsibility of school officials (the state has also delinked its standards for medical contraindications from CDC/ACIP, linking to AAP instead). In Mississippi, the state health department reviews all medical and non-medical (religious) exemption requests.
  • In West Virginia, medical exemptions are reviewed by the state health department and must adhere to guidance from ACIP, AAP, and AAFP. In January 2025, the governor issued an executive order newly allowing religious and personal belief exemptions in the state, setting off a legal battle with the Department of Education. Currently, religious and personal belief exemptions in West Virginia are on hold while the state Supreme Court considers the case. 
  • In Oregon, nonmedical exemptions are allowed but parents must receive counseling about disease risks and vaccine benefits before their child can be granted the exemption. In Washington, religious exemptions simply require parents to complete a form, while personal belief exemptions require parents to receive counseling prior to granting the exemption.
  • In states such as Arizona, Idaho, Oklahoma, and Texas, nonmedical exemptions are granted after parents submit a form requesting them, with no counseling or health professional certification required.

Since 2025, at least 9 states have enacted policy changes that are more permissive for non-medical exemptions. For example, in Texas a new law allows parents to download the state’s non-medical exemption form directly rather than first having to submit a written request to the state’s health department for the form, and Utah has made a student’s vaccine exemption form a part of their permanent school record, allowing the form to remain valid even if a student transfers schools. In New Hampshire, advanced practice registered nurses and physician associates have recently been added as health care providers with the authority to sign school vaccination exemption forms and a new law requires that materials about school vaccine requirements include the statement “Medical and religious exemptions are available under New Hampshire law.”

State Procedures for Setting School Vaccination Requirements

Each state has its own legal and organizational process for setting school entry immunization requirements, which can range from a more statutory process where state legislatures determine most key school vaccination policies, to a more administrative, one where state health departments or other agencies have the responsibility and authority to determine these requirements. Many states have a mix of these elements, such as using a statutory process for some vaccines and an administrative process for others, or where state law determines which vaccines are required while administrative processes determine the specifics such as dosages and schedules. For example:

  • Pennsylvania, Mississippi, South Carolina, and Virginia are states with a more administrative approach, where state health (or other) agencies have significant responsibilities in determining school vaccination requirements. In these cases, the state legislature has established the general requirement that children attending school must be immunized but has delegated authority to state agencies to determine the specific vaccines, dosages, and other technical requirements.
  • In Arkansas and Florida, state legislation sets school vaccination requirements for specific vaccines, while giving the health department responsibility for other vaccines. In Florida, for example, state laws set the requirement that Diphtheria-Pertussis-Tetanus (DPT), MMR, and polio vaccines are required for school entry, but allow the health department to set requirements for other vaccines such as hepatitis A, pneumococcal, and varicella.
  • In Kentucky, Maine, and West Virginia, state laws identify the full set of diseases students must be immunized against, but health departments and/or education departments are empowered with the responsibility to establish dosages, schedules, exemption policies, and other technical requirements.

In many states, childhood vaccination recommendations in the past have been linked to guidance from the CDC/ACIP and in some cases this has included school vaccination policies, such as when states link their allowed medical contraindications for exemptions to CDC/ACIP guidance, as mentioned above. However, since 2025 the Trump administration has sought to make changes to federal vaccine recommendations for children, including by issuing a new federal childhood vaccine schedule in January 2026 (which has been temporarily blocked by a federal judge) and issuing an Executive Order (EO) in August 2026 calling for changes to the federal childhood vaccine schedule and specifically asking States and territories to “consider updating relevant laws and regulations that define the scope of immunization requirements for contexts such as school enrollment and attendance.” In anticipation of and in reaction to the Trump Administration’s policy changes, starting in 2025 a number of states began announcing they will no longer link their own recommendations to those of CDC/ACIP. As of July 30, 2026, most states (30 states, including DC), announced they would no longer follow the CDC/ACIP general childhood vaccine recommendations for one or more childhood vaccines, with 27 doing so for all childhood vaccines, and instead rely on prior recommendations, state recommendations, and/or those of external entities such as AAP. No states have made policy changes in line with the August 2026 EO.  At least 10 state and local jurisdictions have announced specifically that their school vaccine requirements have not changed as a result of the EO.

Status of State Medicaid Expansion Decisions

Published: Aug 21, 2026

The Affordable Care Act’s (ACA) Medicaid expansion expanded Medicaid coverage to nearly all adults with incomes up to 138% of the Federal Poverty Level ($21,597 for an individual in 2025) and provided states with an enhanced federal matching rate (FMAP) for their expansion populations.

To date, 41 states (including DC)   have adopted   the Medicaid expansion and 10 states   have not adopted   the expansion. Current status for each state is based on KFF tracking and analysis of state expansion activity.

These data are also available in a table format. The map may be downloaded as a Powerpoint.

Status of State Action on the Medicaid Expansion Decision (Choropleth map)
Key States with Expansion Activity (Table)

Medicaid Expansion Resources

5 Questions and Answers About Medicaid and Provider Taxes

Published: Aug 20, 2026

The 2025 reconciliation law imposes significant new restrictions on states’ ability to generate Medicaid provider tax revenue, including prohibiting all states from establishing new provider taxes or from increasing existing taxes as well as reducing existing provider taxes for states that have adopted the Affordable Care Act (ACA) Medicaid expansion. Medicaid is jointly financed by the federal government and the states, with the federal government guaranteeing states federal matching payments with no pre-set limit. In federal fiscal year (FFY) 2024, the federal government paid 65% and states paid 35% of total Medicaid costs. States are permitted to finance the non-federal share of Medicaid spending through multiple sources, including state general funds, health-care related taxes (referred to as “provider taxes” throughout this brief), and local government funds.

Changes to provider tax rules will have significant effects on state budgets and may make it difficult for states to maintain current Medicaid spending without increasing state general fund spending; but could increase transparency around Medicaid financing. The changes come at a time when states are already experiencing overall slower revenue growth, and it is unclear how states will be able to make up the lost revenues. The changes could exacerbate existing state budget challenges and result in lower provider payment rates or reductions in Medicaid benefits or coverage, although the effects will vary by state.

This issue brief uses data from KFF’s 2025-2026 survey of Medicaid directors and from a proposed rule on provider taxes to describe states’ current provider taxes, explore how rules governing provider taxes are changing because of the 2025 reconciliation law and the regulations implementing that law, and summarizes which changes may affect each state.

1.How have states used provider taxes to help finance the state share of Medicaid?   

KFF’s 2025 Medicaid Budget Survey found that the majority of state Medicaid spending came from general fund revenues, but provider taxes contributed 18%. States have considerable flexibility in determining how to finance the state (or non-federal) share of Medicaid payments, within certain limits. Across all states, most of the state share of Medicaid spending comes from state general funds, but there is considerable variation in how much states rely on other funding sources. KFF’s 2025 Medicaid budget survey found that general funds accounted for a median of 70% of the non-federal share in state fiscal year (FY) 2026 enacted budgets, while provider taxes accounted for 18%, and funds from local governments or other sources accounted for 6% (this is relatively similar to 2018 data on non-federal share funding sources reported by the Government Accountability Office (GAO) and 2024 data on general fund spending from the National Association of State Budget Officers (NASBO)). 

All states but Alaska finance part of the state share of Medicaid funding through at least one provider tax and 41 states have three or more provider taxes in place (Figure 1). Medicaid provider taxes are defined as those for which at least 85% of the tax burden falls on health care items or services or entities that provide or pay for health care items or services (see Social Security Act, Section 1903(w)(3)(A)). Provider taxes may be imposed as a percentage of provider revenues or using an alternative formula such as a flat tax on the number of facility beds or inpatient days. States use provider tax revenues to fund Medicaid “base” rates and supplemental payments; to finance eligibility expansions, including the ACA Medicaid expansion; or to more generally support the Medicaid program. Over time, states have increased their reliance on provider taxes, with expansions often driven by economic downturns or a desire to fund eligibility expansions or provider reimbursement increases. Beyond helping finance the state share of Medicaid, permissible tax arrangements may have potential financial benefits for providers who are subject to the tax and serve a high volume of Medicaid patients.

All States but Alaska Use Provider Taxes To Help Finance the State Share of Medicaid Spending (Choropleth map)

Provider taxes are most common for institutional providers. That includes hospitals (47 states), nursing facilities (45 states), and intermediate care facilities for people with intellectual or developmental disabilities (33 states, Figure 2). Provider tax revenues often finance supplemental payments to institutional providers, which may be a major source of revenues for those providers. Payment policies vary considerably by state, and research has shown that Medicaid base payment rates are below those of Medicare and often below hospitals or nursing facilities’ costs of providing services to Medicaid enrollees, causing some states to rely more heavily on supplemental payments than others to help cover costs. Beyond institutional providers, states have taxes on managed care organizations (MCOs) (22 states), ambulance providers (21 states), and “other” provider types (9 states) such as ambulatory care facilities and home care providers. Provider tax revenues are most likely to be near the 6% safe harbor limit (described in more detail below) for nursing facilities followed by hospitals and intermediate care facilities for people with intellectual or developmental disabilities (Figure 2).

Provider Taxes Are Most Common for Institutional Providers (Stacked column chart)

CMS estimates that states will collect nearly $100 billion in provider tax revenues in 2026, mostly from hospital taxes (Figure 3). Historically, the federal government did not provide consistent or comprehensive publicly available data about states’ provider tax policies or revenue collections. In June 2024, the Medicaid and CHIP Payment and Access Commission (MACPAC), called for increased transparency over how states financed the non-federal share of Medicaid payments. However, CMS requested additional data from states about their provider taxes in 2025 and 2026. Using those data and their own projections, CMS estimates that tax revenues in calendar year 2026 will be $98.6 billion, with $61.8 billion coming from taxes on hospitals and $28.1 billion coming from taxes on managed care organizations.

Over 90% of Provider Tax Revenues Come from Hospitals and Managed Care Organizations (MCOs) (Donut Chart)

2. What federal rules governed provider taxes before the 2025 reconciliation law?

Since the 1990s, federal rules governing provider taxes have included three core components—requiring taxes to be “broad-based,” “uniform,” and not hold providers “harmless.” Provider taxes were established in the 1980s, but particularly aggressive use of provider taxes following their establishment in the 1980s led to statutory and regulatory limitations beginning in the 1990s. Federal rules prior to passage of the 2025 reconciliation law specified that provider taxes must be:

  • Broad-based, which means the tax is imposed on all providers within a specified class of providers (e.g., the tax cannot be imposed only on providers that see primarily Medicaid patients);
  • Uniform, which means the tax must apply equally to all providers within the specified class (e.g., the tax rate cannot be higher on Medicaid revenue than non-Medicaid revenue); and
  • Not hold taxpayers (providers) “harmless,” which means states are prohibited from directly or indirectly guaranteeing that providers will receive their tax costs back (i.e., be “held harmless”).

To ensure tax programs are “broad-based,” CMS has specified 19 classes of providers (see 42 CFR Section 433.56). States may obtain “uniformity waivers” of the requirements that taxes be broad-based and uniform if the state can prove the net effect of the tax is “generally redistributive,” and the amount of tax is not directly related to Medicaid payments. In assessing whether provider taxes comply with federal laws, regulations specify that the hold harmless requirement does not apply when the tax revenues comprise 6% or less of net patient revenues from treating patients (see 42 CFR Section 433.68), a level sometimes referred to as a “safe harbor” or “hold harmless” limit.

Changes in the 2025 Reconciliation Law

The 2025 reconciliation law, signed by President Trump on July 4, 2025, imposes significant new restrictions on states’ ability to generate Medicaid provider tax revenue. The Congressional Budget Office (CBO) estimated provider tax policy changes from the 2025 reconciliation law would reduce federal Medicaid spending by $226 billion between 2025 and 2034. Those savings reflect the following changes to federal rules:

  • An effective prohibition on new provider taxes or increases to existing ones ($89 billion in savings). The law effectively prevents the enactment of any new provider taxes by establishing a hold harmless limit of 0% for any taxes that were not in effect as of July 4, 2025. It also prevents any increases to existing provider taxes, which are capped at their rates as of July 4, 2025.
  • Reduced limits on provider taxes in states that adopted the Affordable Care Act (ACA) Medicaid expansion ($102 billion in savings).  Beginning in FFY 2028, the law gradually reduces the hold harmless limit for states that have adopted the ACA expansion by 0.5% annually until the safe harbor limit reaches 3.5% in FFY 2032. The new limits apply to all provider taxes except for those levied on nursing facilities and intermediate care facilities.
  • Revisions to the conditions under which states may receive uniformity waivers ($35 billion in savings). Effective July 5, 2025, the law prohibits states from using uniformity waivers if the tax charges higher or lower rates based on the volume of Medicaid revenues or patients.

Changes in the July 2026 CMS Proposed Rule

CMS released a proposed rule in July 2026 to implement the hold harmless provisions in the 2025 reconciliation law, which included some provisions not required under the law. The list below highlights some of the key provisions included in the proposed rule:

  • Broader interpretation of taxes “in effect.” Under the proposed rule, CMS would recognize provider taxes as being in effect as of July 4, 2025 or earlier if they had been enacted. This is less restrictive than guidance issued in November 2025, which also required that all applicable uniformity waivers to have been approved by July 4, 2025 and for states to be “actively collecting” revenues as of July 4, 2025.
  • Establishing health insurers as a permissible class of providers. Although not required by the 2025 reconciliation law, the rule proposes to add a new “health insurer” provider class to expand CMS oversight of health-care related taxes that goes beyond the existing “MCO” provider class including Health Maintenance Organizations and Preferred Provider Organizations. The proposed rule does not define the new class, but CMS is seeking comments on the potential scope of the new provider class. Such taxes would be subject to all other requirements governing Medicaid provider taxes, including new limits in the 2025 reconciliation law. CMS notes that these taxes are often imposed through state insurance commissions or departments.
  • Discontinuation of the 75/75 test. The 2025 reconciliation law did not address the “75/75” test, under which taxes exceeding the hold harmless limit could remain permissible as long as more than 75% of taxpaying providers do not receive more than 75% of the cost of the tax back through enhanced Medicaid or other state payments. Starting in FFY 2027, the proposed rule would discontinue the 75/75 test.
  • Enhanced Reporting Requirements and Compliance System. The proposed rule would significantly expand state reporting requirements and introduce retrospective CMS review to determine ongoing state compliance with the new hold harmless limits. States would be required to submit data (interim in 2026 and final in 2028) to CMS to determine applicable hold harmless limits as of July 4, 2025. States would also be required to submit quarterly reports beginning October 1, 2026, supplying tax collection data as well as information on how tax revenues are used by the state and whether public providers are exempt from the tax.

Under the proposed rule, CMS estimates that federal Medicaid spending would decrease by $246 billion over the next ten years (2026- 2035). This is similar to the CBO estimates although the CBO estimate does not include effects for the year 2035, which accounted for $44 billion of CMS’ total federal spending reduction. While the difference in estimates is relatively small, there are a few key differences in the agencies’ assumptions:

  • States response. CBO assumed that states would replace 50% of the lost provider tax revenues with other funding sources but CMS assumes they will only replace 30%.
  • Coverage loss. CBO estimated that provider tax changes in the 2025 reconciliation law will increase the number of uninsured people by 1.2 million by 2034, but CMS estimates that there will be no enrollment loss associated with the loss of revenues. 

4. Which states may face reductions in existing provider tax revenues?

States that have adopted the ACA Medicaid expansion and have certain provider taxes above the new hold harmless limits will face reductions in existing provider tax revenues. KFF data show that an estimated 31 states will have to reduce one or more provider taxes on hospitals, MCOs, or ambulances because of the lower hold harmless limits in ACA expansion states (Figure 4). Additional states are likely to be affected because of taxes on other classes of providers. Hospital taxes are the most frequently affected, with 28 of the 31 affected states having a hospital tax over 3.5% of net patient revenues as of July 1, 2025. Over half of the Medicaid provisions in the 2025 reconciliation law apply only to ACA expansion states, including the lower hold harmless limits. Those changes—coupled with lower provider tax revenues—may make it particularly difficult for ACA expansion states to navigate a challenging fiscal climate and increasing numbers of uninsured residents.

If CMS’ proposed regulation is finalized with the new health insurer provider class, additional states will be affected, though it is unclear how many states currently have such taxes in place. CMS’ decision to establish health insurers as a provider class for the purposes of Medicaid provider tax rules means that additional taxes will be subject to new hold harmless limits and in ACA expansion states, additional taxes may be subject to the decreasing hold harmless limits over time.

The Effective Prohibition on New or Increased Provider Taxes Could Impact All States, With Expected Cuts to Existing Taxes in At Least 31 States (Choropleth map)

5. Which states may need to rework their “uniformity waivers?”

Uniformity waivers have allowed states to waive the requirement that provider taxes be broad-based and uniform if CMS determines that the tax is “generally redistributive.”  Provider taxes established through such waivers have generally taxed some types of providers within a class more heavily than others. States may use uniformity waivers to achieve policy goals such as limiting tax burdens for sole community hospitals, rural hospitals, or other vulnerable providers; but states have also used the waivers to impose taxes primarily on Medicaid providers. The disproportionate taxation of Medicaid providers has raised CMS concerns, including during the Biden Administration, and in May 2025, the Trump Administration released a proposed rule that aimed to address those concerns. The final rule was published on February 2, 2026 (Box 2).

The 2025 reconciliation law prohibits states from using uniformity waivers if the tax charges higher or lower rates based on the volume of Medicaid revenues or patients. The law specifies that taxes may not be considered generally redistributive if the state effectively varies tax rates based on the providers’ Medicaid revenues or patients, even if the tax does not explicitly name “Medicaid” when establishing the tax rates. The requirement is largely targeted at MCO taxes but may also apply to other provider tax types. It is effective as of July 5, 2025, but the Secretary may give states up to three fiscal years to come into compliance. The final rule on uniformity waivers provides states with transition periods that depend on what type of tax the waiver applies to and the most recent date of CMS approval for the waiver. Specifically:

  • For taxes on MCOs with a waiver approval within 2 years of April 3, 2026, states have until the end of the current calendar to transition their taxes (this is expected to be the case in California and at least three other states).
  • For all other taxes on MCOs, states have until the end of FY 2027 (which in most states, means they would need to be complying by July 1, 2027).
  • For taxes on entities other than MCOs, states have through the end of FY 2028 to come into compliance.

States may come into compliance by either submitting a new waiver proposal that meets the new requirements from the final rule (Box 2) or they may otherwise modify their tax such that no waiver is necessary.

The final rule states that new limits on uniformity waivers will affect at least nine taxes in at least seven states, with effects starting as early as January 1, 2027 (Figure 5). CMS did not identify the specific states in the final rule, but in the proposed rule, CMS specifically named California, Massachusetts, Michigan, and New York as being affected.  KFF and other researchers expect that the other three states are Illinois, Ohio, and West Virginia. The final rule states that existing MCO taxes would now be prohibited in seven states unless the taxes were modified, and that within those seven states, there were at least two additional taxes affected, including one on hospitals and one on nursing homes. However, elsewhere, in the preamble to the final rule, CMS indicated that there were two nursing facility taxes that would now be prohibited. (It’s unclear whether the second nursing facility tax is within the seven states or in an eighth state.) CMS indicates that additional taxes may need to be modified or eliminated, but it is unknown which states have such taxes or what types of providers the taxes pertain to. Beyond uncertainty surrounding the scope of affected taxes, much remains unknown about how states may respond to the new rule.

Box 2: CMS’ Final Rule on Uniformity Waivers

Since 1993, CMS has assessed whether proposed taxes are “generally redistributive” using a statistical formula that assesses whether a state’s tax has a tendency to “derive revenues from taxes imposed on non-Medicaid services in a class and to use these revenues as the State’s share of Medicaid payments” (58 Fed. Reg. 43164, August 13, 1993). Consistent with Section 71117 of the 2025 reconciliation law, the February 2026  final rule prohibits all taxes that have differential tax rates based on Medicaid revenues or patients even if they meet the statistical test. The final rule focuses primarily on managed care organization (MCO) taxes and cited examples where nearly all tax revenues were paid by Medicaid MCOs with private health plans paying nearly none, but notes other types of taxes would also be affected.

New Requirements for “Uniformity Waivers” Will Force Changes to Provider Taxes in at Least Seven States (Choropleth map)

This work was supported in part by Arnold Ventures. KFF maintains full editorial control over all of its policy analysis, polling, and journalism activities.

Provider Taxes Not Exempt From the Reconciliation Law’s Reduction in the Safe Harbor Limit for ACA Expansion States (Table)

HHS Public Health Policy Actions Under the Trump Administration 2025-2026

Published: Aug 19, 2026

Note: Originally published on Nov. 12, 2025, this resource is updated as needed, most recently on August 12, 2026, to reflect additional developments. 

Since assuming office for a second term, President Trump and officials in his administration have instituted numerous policy actions through the Department of Health and Human Services (HHS) affecting public health in the U.S. This resource lists and briefly describes key actions in the order in which they were first issued, reported or announced, with subsequent linked actions and related outcomes also included with each entry. As new policy changes occur, they will be added. 

This resource is not meant to be exhaustive of all administration actions related to public health, as many other federal policy changes – including outside of HHS – have public health implications but are not captured here.

Additional KFF resources on administrative actions related to global health, LGBTQ+ health, and mental health and substance abuse are also available.

Date

|

Action/Description

January 20, 2025Presidential Executive Orders precipitate removal of some HHS websites and health data.
– In the first days of his second term President Trump issued a number of Executive Orders (EOs), including EOs that revoked many Biden administration orders and programs, and instituted new federal guidance related to “gender ideology,” “diversity, equity, and inclusion (DEI),” and “merit-based opportunities.” These EOs have implications for public health, particularly related to the collection and presentation of data and websites by the federal government. For example, in response to the EOs, HHS began to remove thousands of websites and numerous federal databases with public health information deemed to be related to DEI, LGBTQ, reproductive health, HIV/AIDS research, health disparities, and more, and limited some data collection and analysis in these areas. A lawsuit was filed to reverse these removals, and some information has been restored over time. In September, the administration agreed to restore all previously removed health-focused websites and data to versions that had existed on January 29, 2025.
February 7, 2025NIH announces change to indirect cost rate guidance.
– As part of grants for health research, the National Institutes of Health (NIH) provides “indirect cost” funding to grant recipients, which supports administration and facilities costs at grantee institutions. On February 7, NIH announced it would apply a new 15% “standard indirect cost rate” on all grants, which would apply to any new grants and to existing grants for expenses as of February 10, 2025. This was challenged in federal court and federal judges placed holds on the policy, first through a temporary restraining order affecting 22 states on February 10, a nationwide preliminary injunction on March 5, and a permanent injunction on April 4; prior rates still apply for the time being. The administration appealed the ruling and legal proceedings continue. If implemented, a 15% indirect cost rate would be a much lower rate compared to historical NIH rates and would amount to a significant cut in funding for institutions performing NIH-sponsored health research.
February 13, 2025Robert F. Kennedy, Jr. confirmed as HHS Secretary under President Trump.
– The Senate voted 52-48, along party lines, to confirm Robert F. Kennedy, Jr. as the Secretary of Health and Human Services.
February 13, 2025President Trump issues Executive Order (EO) establishing MAHA policy agenda and MAHA Commission.
– The EO outlines the purpose and objectives of the Trump administration’s Make American Healthy Again (MAHA) efforts. Stating that the U.S. must “re-direct our national focus…toward understanding and drastically lowering chronic disease rates and ending childhood chronic disease,” it directs federal agencies to “aggressively combat” mental health disorders, obesity, diabetes, and other conditions. It also establishes the MAHA Commission to advise the President, naming Secretary Kennedy as Chair. The EO directs the Commission to submit an assessment on how to combat the “childhood chronic disease crisis” within 100 days, and a strategy to address the crisis within 180 days, setting in motion processes to develop further public health strategies and plans (discussed in other entries below). 
February 14, 2025White House, DOGE initiate “reduction in force (RIF)”, including for HHS personnel.
– The EO outlines the purpose and objectives of the Trump administration’s Make American Healthy Again (MAHA) efforts. Stating that the U.S. must “re-direct our national focus…toward understanding and drastically lowering chronic disease rates and ending childhood chronic disease,” it directs federal agencies to “aggressively combat” mental health disorders, obesity, diabetes, and other conditions. It also establishes the MAHA Commission to advise the President, naming Secretary Kennedy as Chair. The EO directs the Commission to submit an assessment on how to combat the “childhood chronic disease crisis” within 100 days, and a strategy to address the crisis within 180 days, setting in motion processes to develop further public health strategies and plans (discussed in other entries below). 
February 14, 2025President Trump issues Executive Order prohibiting federal funding to schools and universities with COVID-19 vaccine requirements.
– The EO requires HHS to work with the Department of Education to prohibit COVID-19 mandates in schools, by issuing guidelines for compliance and barring federal funds from going to any educational agency, K-12 school, or institution of higher education that requires COVID-19 vaccination to attend in-person education programs (educational vaccine mandates are set at the state level). Educational vaccine requirements are set at the state and local levels. At the time the EO was released in February, no state required K-12 students to be vaccinated against COVID-19 while 15 colleges required Covid vaccines for students. However, by March 14, 2025 all of those colleges had ended their COVID-19 vaccine requirements for students.
February 18, 2025Secretary Kennedy announces public health policy priorities during HHS welcome ceremony.
– In his first remarks to HHS staff, Secretary Kennedy announces the public health priorities for his tenure. This include investigating the childhood vaccine schedule, tackling corruption and promoting transparency, and addressing a “chronic disease epidemic” especially in children, which he says may be linked to pesticides, food additives, antidepressants, microplastics, cellphone emissions, and other factors.
February 28, 2025Secretary Kennedy issues new rule ending public comment requirement for HHS grants and contracts.
– The new rule rescinds a prior HHS policy on “Public Participation in Rule Making” (the “Richardson Waiver,” dating back to 1971) and “re-aligns the Department’s rule-making procedures with the Administrative Procedure Act.”  As a result, “matters relating to agency management or personnel or to public property, loans, grants, benefits, or contracts” are exempt from the notice and comment procedures. This removes what had been a key step in the rulemaking process requiring public notification and a comment period. For example, changes to HHS policies related to work requirements for Medicaid and NIH funding would no longer require public comments under the new rule. This could streamline implementation of HHS policy, but also reduce public visibility on changes before they take effect.  Some lawmakers and public health focused groups have asked HHS to return to the prior requirements under the Richardson Waiver. 
March 7, 2025HHS announces that CDC will conduct a study of factors contributing to the rise in autism in the U.S.
– In statements to the press, HHS officials indicate CDC will initiate a study looking at the factors that are contributing to the rise in autism diagnoses in the U.S.. To date, no new CDC study results on this topic have been released though in a related development, in September 2025 President Trump and HHS leadership announced at a press conference and through a White House Fact Sheet that they believe there is a link between acetaminophen (e.g., Tylenol) use in pregnancy to autism (further details provided below). President Trump and Secretary Kennedy both have a history of linking vaccines and autism, even though there is no evidence of such a link.
March 13, 2025Food and Drug Administration (FDA) releases guidance on 2025-2026 influenza vaccine composition.
– The FDA guidance identifies which influenza virus strains manufacturers should use as components of 2025-2026 influenza vaccines. To develop these recommendations, FDA convened meetings of federal scientific and public health experts, including from FDA, CDC, and Department of Defense, but did not consult with the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) or other professional groups outside the government. FDA had canceled the scheduled VRBPAC meeting on this topic, and the lack of input from outside experts was a break from past years’ practices. In addition, in past years there was active participation and coordination between U.S. federal experts and global technical experts working under the auspices of the World Health Organization (WHO), but official communications with WHO-linked experts has been curtailed since the Trump administration announced in January 2025 that the U.S. was withdrawing its membership from the UN agency.
March 17, 2025NIH initiates termination of numerous grants for HIV prevention and treatment programs.
– The canceled NIH grants include support for researchers investigating use of PrEP, medication used pre-exposure to prevent HIV infections, and programs focused on HIV/AIDS in adolescents and young adults. Even as the first Trump administration supported HIV/AIDS prevention and treatment efforts, including through a highly visible federal effort to “end the HIV epidemic” in the U.S. by 2030, these same programs have now been targeted for cuts (further details below).   
March 17, 2025HHS removes Surgeon General warning declaring gun violence a public health crisis.
– The HHS website was changed, removing a 2024 advisory from the Surgeon General on the public health impacts of gun violence. In addition to removing the Surgeon General’s warning, the administration has rolled back a number of gun safety policies in place during the Biden administration. The White House Office of Gun Violence Prevention, established during the Biden administration was shut down in early 2025. Further, significant numbers of staff at CDC’s Injury Center, which collects data on violent deaths and injuries, and CDC’s Division of Violence Prevention have been let go as part of the Trump administration’s reduction in force efforts.
March 25, 2025HHS and CDC seek to pull back $11 billion in supplemental COVID-19 and public health funding from state and local health departments.
– In a statement, HHS says it intends to pull back $11.4 billion in supplemental funding that had been provided by Congress for state and local public health departments through CDC for pandemic response activities. Following the announcement, on April 1, a group of 23 mostly Democratic-led states sued the Trump administration over the attempt to pull back this funding.  On April 3, a federal judge placed a temporary block on the administration’s actions, and on May 16, another federal judge indefinitely blocked the administration from enacting its funding pull back for the states that are part of the lawsuit. As of late August 2025, almost 80% of the funds initially targeted for cuts by the Trump administration had been restored for the 23 states that won in court. However, funding has not been restored to the remaining states, the majority of which are Republican-led.
March 27, 2025HHS announces a major re-organization and job cuts plan.
– HHS announces plans for a major restructuring of the department, in accordance with President Trump’s February 26 EO on “Implementing the President’s ‘Department of Government Efficiency’ Workforce Optimization Initiative.” The announcement says HHS will create an Administration for a Healthy America (AHA), which would combine several existing HHS offices including the Office of the Assistant Secretary of Health (OASH, which contains the Surgeon General’s Office), the Health Research and Services Administration (HRSA), the Substance Abuse and Mental Health Services Administration (SAMSHA), the Agency for Toxic Substance and Disease Registry (ATSDR), and the National Institute for Occupational Safety and Health (NIOSH). In addition, the Administration for Strategic Preparedness and Response (ASPR) at HHS would be moved under CDC. The announcement also says HHS will reduce its workforce by eliminating 10,000 full-time positions. Combined with other reduction in force efforts, a total of 20,000 HHS workers are expected to lose their jobs.

On May 5, a coalition of 19 Democratic-led states and the District of Columbia filed a lawsuit against the mass firing of federal health workers and re-organization of HHS. On May 10, a court ordered a temporary pause on sweeping federal firings at HHS and other agencies. On July 1, a federal judge blocked mass firings at HHS, saying they are likely unlawful. However, on July 8 the Supreme Court overturned the lower court decisions, allowing the Trump administration to proceed with job cuts. As of August it is estimated that over 20,000 jobs at HHS have already been cut, meaning the administration already met its initial workforce reduction goal.

Regarding re-organization, some organizational changes have been implemented at HHS, with major cuts or closures to public health related offices such as the HHS Office of Infectious Diseases & HIV Policy, the HHS Office of Minority Health, and HRSA’s Bureau of Primary Health Care.  However, other proposals such as the formation of an Administration for a Healthy America (AHA), have not yet been implemented. Implementing AHA to the extent proposed is likely to require approval from Congress, though so far Congress has not acted on legislation codifying these proposals.
March 31, 2025HHS withholds portion of Title X family planning service grants. 
– HHS notifies one in five current grantees of the federal Title X family planning program that a portion of their funding would be temporarily withheld. This funding freeze affects all nine Planned Parenthood grantees, in addition to 7 other nonprofit grantees, and it is estimated that a total of 879 clinics (24% of all Title X clinics) in 23 states are affected. After several months, funds were reinstated to some organizations, but the Planned Parenthood grantees have still not had their funding reinstated.
April 1, 2025HHS ends federal support for the “Safe to Sleep” program, which focuses on prevention of infant deaths during sleep.
– The Trump Administration ends federal participation in Safe to Sleep, a national campaign that focused on educating parents of newborns about safer sleeping practices for infants that can prevent death. The program, supported through the NIH’s National Institute of Child Health and Human Development (NICHD) Office of Communications in recent years, had been in existence for over 30 years and had contributed to a major decline in sudden infant deaths. The NICHD office was eliminated on April 1, along with federal support for “Safe to Sleep.”
April 2, 2025HHS requires CDC to reduce contract spending by $2.9 billion as part of DOGE cost reduction efforts.
– According to reports, HHS orders CDC to reduce its contract spending by $2.9 billion by April 18.CDC contract funding has been used to support several services at the agency including security, cleaning, and computers/technology. The sudden requirement to cut this spending by approximately 35% affects CDC operations. 
April 7, 2025HHS Secretary Kennedy announces changes to fluoride policies.
– Secretary Kennedy announces a plan to implement a number of changes to federal policy related to water fluoridation, including stating that CDC will stop recommending water fluoridation as a public health intervention (though to date, HHS and CDC still recommend community water fluoridation). In addition, Kennedy says the defunct Community Preventive Services Task will be revived and reconvened, with a goal of studying and making recommendations about water fluoridation. Kennedy also called on states to ban fluoride in their drinking water. Already this year Utah and Florida have banned community water fluoridation, the first states ever to do so.
April 17, 2025FDA informs Pfizer/Moderna that mRNA COVID vaccines will require an expanded warning label about myocarditis.
– In letters sent April 17, the FDA informs Pfizer and Moderna they must alter the warning labels for their COVID-19 mRNA vaccines to include expanded risks for myocarditis and pericarditis. Previously, the warning labels for these vaccines noted risks for these conditions for those aged 18 to 24 years (Moderna) and 12 to 17 years (Pfizer). However, updated labels are required to include new language saying “the observed risk of myocarditis and pericarditis following vaccination with mRNA COVID-19 vaccines has been highest in males 12 through 24 years of age” and that “persistence of abnormal cardiac magnetic resonance imaging (CMR) findings that are a marker for myocardial injury was common.”  According to FDA, the labels must also include more information about these conditions and their health risks.  Since the letters were sent, the companies have complied with the new FDA requirements. FDA approved the updated label language on June 25.
April 22, 2025FDA and HHS announce measures to phase out use of petroleum-based food dyes.
– FDA and HHS announce a series of steps the federal government will take to remove petroleum-based synthetic dyes from the U.S. food supply. These actions include initiating a process to revoke federal authorization for two such dyes and planning phase-outs by the food industry for others. In addition, the government will support research on food additives and children’s health and authorize natural alternative coloring options. Under the current plan, the phase-outs will occur through voluntary action taken by food companies.
May 1, 2025HHS announces a $500 million investment in a “next generation universal vaccine platform.”
– HHS and NIH announce that $500 million in funding will be directed to a new effort  to develop a “universal vaccine platform for pandemic-prone viruses.” The platform uses inactivated whole viruses, and is part of a broader federal effort to develop universal vaccines called “Generation Gold Standard.” The funds for this new investment appear to be re-purposed vaccine development funds from the Biden Administration’s NextGen initiative to develop next generation COVID-19 vaccines.
May 2, 2025White House Releases FY 2026 President’s Budget Request calling for major fundings cuts at HHS.
– The White House released an outline of the administration’s budget request for FY2026 and on May 30, the White House submitted the full Budget Request for FY2026 to Congress. The request proposes steep cuts to the HHS budget, including cuts for CDC, HRSA, SAMHSA, NIH, eliminating the Hospital Preparedness Program at ASPR, and reducing funding and cutting some programs focused on HIV/AIDS research and response. The budget request also asks Congress for $500 million to support a new “Administration for a Healthy America (AHA)” and MAHA-related priorities. The President’s Budget Request is only a proposal, as it is Congress that ultimately decides how much money the federal government appropriates. So far, Congressional spending bills for FY2026 have not included cuts to HHS of the magnitude requested by the President, and Congress has not provided the requested $500 million for AHA though budget negotiations continue.   
May 5, 2025White House Executive Order restricts funding and increases oversight for “gain of function” research at HHS.
– In an EO titled “Improving the Safety and Security of Biological Research” the White House cites concerns with federally funded “gain-of-function” (GOF) research on biological agents and states the Biden administration allowed dangerous GOF research to occur without sufficient oversight. The EO directs the Secretary of HHS to coordinate with other relevant Executive branch offices to establish guidance to end federal funding of “foreign entities” where GOF is being undertaken or in countries lacking oversight of GOF research. The EO requires the relevant Executive offices to submit updated policies and guidance for all federally supported GOF-related research, and to develop a strategy for managing risks of non- federally funded GOF research. The full implications of the EO are not yet clear, as the Executive branch offices must develop and implement specific guidance and regulations. According to outside experts, potential benefits of the EO include more transparency and stricter enforcement of dangerous research, while potential risks include hindering beneficial research that is not GOF and researchers choosing to curtail beneficial research to avoid potential repercussions under evolving federal restrictions.
May 20, 2025FDA leaders announce clinical trials will be needed for approval of certain new COVID vaccine formulations.
– In a medical journal article, FDA leaders indicate that going forward, for federal approval of new or updated COVID-19 vaccines (“boosters”) for use in individuals who are not considered at higher risk (defined as persons 65 or older or those with certain health conditions), will require vaccine makers to present evidence from randomized, placebo-controlled trials that demonstrate safety and efficacy. The announced policy is a departure from prior years when FDA did not require new trial data to authorize or approve boosters, but instead allowed approvals based on immune response evidence. The new policy could hinder investments by pharmaceutical companies in developing new COVID vaccine formulations, given the greater expense and time required to conduct new, full clinical trials.
May 22, 2025MAHA Commission Report on childhood chronic disease published.
– The first official report from the MAHA Commission (established by the February 13 EO discussed above) discusses factors contributing to a “chronic disease crisis” for U.S. children and provides a “call to action”. The report highlights four main drivers of the crisis: poor diet (primarily due to consumption of ultra-processed foods), exposure to chemicals, lack of physical activity and chronic stress, and “overmedicalization (excessive use of prescription drugs, such as antidepressants). The report calls for federal agencies to “close critical research gaps and guide efforts to better combat” these issues. It also says the MAHA Commission will develop and release a strategy in August (discussed below). The report expanded on the ideas initially outlined in the February EO and provided more details on Secretary Kennedy’s priorities to address chronic disease in children. There was some criticism of the report after its publication, with experts questioning some of the evidence and conclusions and pointing out significant errors and studies cited that did not exist, which indicated that artificial intelligence was likely used to help write the report. 
May 23, 2025Administration ends NIH funding for several HIV vaccine research projects. 
– NIH notifies two grant recipients working on broadly neutralizing antibody research for HIV vaccines of the cancelation of their funding.  The canceled grants supported early-stage vaccine development research that uses a different approach than other HIV vaccine candidates. Some other HIV vaccine candidates remain in the development pipeline and clinical trials continue, but the absence of this early-stage research could jeopardize the development of additional candidates going forward.
May 27, 2025HHS Secretary Kennedy announces CDC will no longer recommend COVID vaccines for healthy pregnant women and children.
– In a video post on X, Secretary Kennedy announces “the COVID vaccine for healthy children and healthy pregnant women has been removed from the CDC recommended immunization schedule.” The announcement was a departure from the typical process for changing vaccine recommendations, which includes review and input from the Advisory Committee on Immunization Practices (ACIP) and a notification from the CDC Director. Initially, the implications of changing CDC guidance without ACIP input were unclear given that no-cost insurance coverage for vaccination is linked to ACIP and CDC recommendations. On May 30, CDC changed the language on its website for COVID-19 vaccines, removing its prior recommendation for pregnant women to be routinely vaccinated and stating that healthy children 6 months to 17 years old could be vaccinated in consultation with health care providers/parents – a recommendation known as “shared decision-making,” which would mean insurance would still have to cover such vaccinations. On July 7, a coalition of professional medical organizations filed a lawsuit against HHS over the new COVID-19 vaccine recommendations, saying the department did not follow federal procedures in making the change and also mislead the public on the issue (on January 6, 2026, a federal court confirmed these plaintiffs have standing to challenge HHS’s actions on the COVID-19 vaccine recommendations, allowing the case to proceed to arguments). On August 19, independent expert groups, including the AAP, issued their own recommendations for COVID vaccines in infants and young children in contrast with CDC’s new recommendations.  On Aug 22, ACOG issued their own recommendations for pregnant patients.
June 9, 2025HHS Secretary Kennedy announces removal of all sitting members of ACIP.  
– In a post on X and a subsequent HHS press notice, Secretary Kennedy announces that all 17 sitting members of the CDC’s Advisory Committee on Immunization Practices (ACIP) are dismissed, to be replaced with new members selected by the Secretary. Kennedy says the move is “prioritizing the restoration of public trust above any specific pro- or anti-vaccine agenda.” The HHS Secretary does have the discretion to remove and nominate ACIP members, though no previous Secretary has dismissed all ACIP members at once. In a subsequent X post on June 11, Kennedy announces the nomination of eight new members to ACIP, several of whom have been critical of COVID-19 vaccines and have expressed concerns about harms caused by vaccinations more generally. In a later press release from September 15, HHS announces five more members to be appointed to ACIP, including several with a history of criticism of COVID-19 vaccine policies. 
June 17, 2025FDA announces National Priority Vouchers for expedited regulatory review of new drugs that support “U.S. national interest.
– FDA announces a Commissioner’s National Priority Voucher (CNPV) program, which can be “redeemed by drug developers to participate in a novel priority program” that shortens regulatory review time from 10-12 months to 1-2 months. FDA says it will determine the availability of vouchers for companies that are aligned with the “national health priorities” of: addressing a health crisis in the U.S.; delivering more innovative cures for the American people; addressing unmet public health needs; and, increasing domestic drug manufacturing as a national security issue. On October 16, FDA announced the first nine CNPV recipients, and on November 6, announced six more recipients.  The impact of this new priority voucher program on speeding drug approvals and onshoring drug manufacturing capacity is as yet unclear. In addition, there are several other existing priority review processes at FDA so adding another could strain FDA staff capacity at the same time there has been significant reductions in FDA’s staff and budget.  These strains have already slowed FDA review times in general.
June 18, 2025FDA approves lenacapavir – a new HIV prevention drug.
– FDA approves Gilead Sciences’ lenacapavir, a new injectable PrEP drug that has been shown to be highly effective at preventing HIV infection, and which requires just one dose every 6 months, making it the first ever twice-a-year drug option for HIV prevention. In September, CDC issued clinical guidance for use of injectable lenacapavir as PrEP, though that guidance did not include reference to transgender people, a group intentionally included in the clinical trials and at increased risk of HIV. FDA’s approval also precipitated a review by the World Health Organization (WHO) and on October 6, WHO pre-qualified lenacapavir for prevention of HIV. WHO pre-qualification can speed regulatory approval for the drug in many low- and middle-income countries with a high burden of HIV/AIDS and can also allow for global health mechanisms like the Global Fund to Fight AIDS, Tuberculosis and Malaria to procure the drug.
June 25-26, 2025The newly reconstituted ACIP makes recommendations and policy changes related to RSV and influenza vaccines, and designates new workgroups on hepatitis B, MMRV, and the childhood immunization schedule.
– ACIP votes to recommend respiratory syncytial virus (RSV) injections for babies and RSV vaccine for people 50 and older, and a ban on the use of thimerosal in multi-dose influenza vaccine vials. ACIP also agrees to stand up three new workgroups that will review the U.S. childhood vaccination schedule, hepatitis B guidance, and combination MMRV vaccine.  Subsequently, on July 3, CDC issued new RSV guidance that mirrored ACIP recommendations. On July 23, Secretary Kennedy enacted ACIP’s recommendation on thimerosal, rescinding federal recommendations for any influenza vaccines containing thimerosal (a change that only affects a very small percentage of the overall influenza vaccine market that is comprised of multidose vials).
July 1, 2025HHS alters program requirements and withholds funding from sex education and teen pregnancy prevention programs.
– HHS notifies all Teen Pregnancy Prevention (TPP) program grantees and Personal Responsibility Education Program (PREP) grantees in 46 states and territories that their material must align with President Trump’s executive orders, including those that ban the promotion of gender inclusivity, risk losing federal funding. TPP is a national grant program that funds grantees to replicate, develop, test, and evaluate evidence-based approaches to prevent teen pregnancy, while PREP awards grants to state agencies to use evidence-based models in educating adolescents on both abstinence and contraception. In August, the Trump administration cancelled a $12.3 million PREP grant to California after state officials refused to revise curricula in compliance with the EOs. In September 2025, 16 states and D.C. sued HHS alleging that the new PREP grant conditions are unlawful, unconstitutional, and harmful to gender diverse youth. Similarly, a federal judge blocked the HHS policy changes for TPP in October 2025.
July 2, 2025CDC deactivates its emergency response for H5N1 influenza (bird flu) and limits tracking and reporting of data on bird flu infections in humans and animals.
– CDC ends its emergency response for H5N1 bird flu in the U.S., which had been active since April 4, 2024. CDC reports the change is due to a decline in animal infections and no reports of human cases since February 2025. CDC also says data on the number of people tested for H5N1 will be reported only monthly, and no further data on infection rates in animals will be reported on the CDC website. Even so, reporting from states showed the number of H5N1 cases in birds, which had declined over the summer, began to increase again in fall 2025. However, much of the federal research and response efforts for H5N1 have been closed down or significantly limited following funding and staff cuts and a prolonged government shutdown. The limited federal tracking and reporting of H5N1 infections can slow identification of outbreaks and potentially slow response times.
July 9, 2025HHS Secretary Kennedy cancels a scheduled meeting of the U.S. Preventive Services Task Force (USPSTF).
– Secretary Kennedy cancels a meeting of the USPSTF several days before it was scheduled to take place, with no reason given and no re-scheduled meeting date provided. Typically, the task force meets three times a year, though no meeting has yet occurred under Secretary Kennedy. USPSTF is responsible for reviewing and recommending preventive health services. USPSTF recommendations have implications for what services insurers must cover with no cost-sharing, under the Affordable Care Act (ACA). Such services can include screening tests, behavioral counseling, and medications that can prevent diseases and illness (other than vaccines, which are tied to ACIP recommendations). However, along with other parts of the ACA, USPSTF has faced court challenges. On June 27 (prior to Kennedy’s cancelation of the meeting), while the Supreme Court ruled the ACA requirement that insurers cover USPSTF-recommended services is indeed constitutional, it also found that the HHS Secretary has the power to add and remove USPSTF members at will, which underscores the possibility that Secretary Kennedy may choose to dismiss some or all of the existing USPSTF members and appoint new members (as Kennedy has done with ACIP), or simply not name any new members, and has the power to choose not to adopt USPSTF recommendations. In light of Kennedy’s cancellation and the Supreme Court ruling, 104 public health focused organizations called on Congress to “protect the integrity of the USPSTF” through legislative action. The subsequent USPSTF meeting was scheduled to occur in November but that was also canceled, with HHS citing the government shutdown as the reason. Meetings in March 2026 and July 2026 were also canceled.
July 31, 2025FDA announces new safety label requirement for opioid pain medications.
– The FDA says will require safety labels on opioid medications so that users can better understand that risks of long-term opioid use. The updated labels should include a summary on the risk of addiction, misuse, and overdose, treatment guidance and the risk of higher doses, how to safely discontinue opioid use, drug interactions, digestive complications, and overdose reversal medications. Drug companies received notification letters and have 30 days to submit updated labels for review.
July 31, 2025HHS Secretary Kennedy swears in Susan Monarez as CDC Director.
– In a statement welcoming the newly Senate-confirmed CDC Director, Secretary Kennedy says Monarez has “unimpeachable scientific credentials” and he has “full confidence in her ability to restore the CDC’s role as the most trusted authority in public health.” However, 28 days later (on August 27) the White House removed Monarez from her position at CDC. According to Kennedy, she was removed because he lost trust in her ability to serve as CDC Director and to implement the policies of the Trump Administration. According to Monarez, she was removed because she would not provide “blanket approval” for vaccine policy changes in advance and would not fire, as requested by Kennedy, CDC employees without cause. On August 28, Secretary Kennedy announced in a letter to CDC staff that Deputy Health and Human Services Secretary Jim O’Neill would serve as acting CDC Director.
August 1, 2025Newly announced CDC policy prevents outside professional medical and public health organizations from participating in working group meetings of ACIP.
– Officials at HHS notify professional medical organizations such as the American Academy of Pediatrics (AAP), the American Medical Association (AMA), the American College of Obstetricians and Gynecologists (ACOG), and others that they will be excluded from joining ACIP working group discussions going forward. Professional groups representing medical doctors and other stakeholders in vaccine policies have long participated as non-voting members, including in ACIP working groups. Working groups are typically responsible for helping review available data about topics prior to ACIP meetings, and helping develop recommendation language for ACIP to vote on, as well as other activities in support of ACIP. While the outside groups can be present and can participate in full ACIP meetings, the new policy removes them from providing any input through working groups.
August 5, 2025HHS announces a “coordinated wind down” of $500 million in federal funding for mRNA vaccine research
– HHS announces that it will cancel and begin to wind down mRNA vaccine development activities funded through the Biomedical Advanced Research and Development Authority (BARDA). In total, HHS reports it is canceling 22 projects worth nearly $500 million because “these vaccines fail to protect effectively against upper respiratory infections like COVID and flu…Going forward, BARDA will focus on platforms with stronger safety records and transparent clinical and manufacturing data practices.”  mRNA COVID-19 vaccines are effective in preventing severe illness and death from the disease, and mRNA vaccine technology has potential applications for other infectious diseases, as well as chronic diseases like cancer. The cancellation removes the bulk of U.S. federal funding for mRNA research, leaving questions about future progress by the U.S. in this area of vaccine technology.
August 15, 2025HHS reinstates the defunct Task Force on Safer Childhood Vaccines.
– The original Task Force on Safer Childhood Vaccines, a federal panel created by Congress in 1986 “to improve the safety, quality, and oversight of vaccines” was disbanded in 1998, but HHS announces that the group will be re-instated at NIH with participation from officials at FDA, CDC, and other government agencies. The goal of the reconstituted Task Force will be “the development, promotion, and refinement of childhood vaccines that result in fewer and less serious adverse reactions than those vaccines currently on the market, and improvements in vaccine development, production, distribution, and adverse reaction reporting” to help increase federal oversight and investigation of vaccine injuries.  The Task Force will come together to develop recommendations to be submitted to Congress within two years, with updates every two years after. Reinstatement of this panel has been a goal of anti-vaccine advocates for years, including the Children’s Health Defense, the anti-vaccine organization Secretary Kennedy founded, which supported a lawsuit earlier in 2025 against Kennedy that sought to require him to reconvene the Task Force.
August 27, 2025FDA approves COVID-19 vaccines for 2025-2026, while limiting scope of approval to certain ages and risk profiles.
– FDA approves updated COVID-19 vaccines for 2025-2026, but also limited the approval to persons 65 and older and those between 18 and 64 with a health condition that puts them at higher risk for severe disease. Previously, the FDA had approved the use of vaccines for all ages (over 6 months) regardless of risk profile.
September 9, 2025MAHA Commission releases strategy to address childhood chronic disease.
– A new MAHA Commission strategy document outlines actions the federal government is taking or plans to take to address childhood chronic disease in the U.S. These include “more than 120 initiatives” that together represent “the most ambitious national effort ever to confront childhood chronic disease,” and which outline a “blueprint for the entire government” to address chronic disease. Elements of the strategy include: changing federal science and research priorities, reforming dietary guidelines, changing nutrition and food regulations through reducing additives and ultra-processed foods, and improving effort to raise public awareness about chronic disease. The strategy highlights the risks of vaccine injuries, fluoride in drinking water, among many other areas.
September 18, 2025Secretary Kennedy renews the declaration of the national opioid crisis as a public health emergency.
– In a declaration on an HHS website, Secretary Kennedy renews the declaration of the opioid crisis as a national public health emergency (PHE).  The opioid crisis was initially declared a public health emergency in 2017; renewal is required every 90 days to continue the PHE.
September 19, 2025Secretary Kennedy announces that the FDA will launch a new review of mifepristone.
– Secretary Kennedy announced that the FDA will undergo a review of the current Risk Evaluation and Mitigation Strategy (REMS) for mifepristone, due to new evidence including an April 2025 report from the Ethics and Public Policy Center (EPPC) which claims that mifepristone has a higher rate of adverse events than previously reported. This report has drawn criticism due to methodological flaws and lack of transparency regarding its data sources.
September 19, 2025ACIP makes several new recommendations related to MMRV and COVID-19 vaccines
– In its September 18-19 meeting, ACIP members vote on several new recommendations including to no longer recommend the combination MMRV (measles, mumps, rubella, and varicella) vaccine for children under the age of 4 and instead to recommend that children in this age group receive measles, mumps, and rubella (MMR) vaccine separately from the varicella vaccine (V). In addition, ACIP members vote to change what had been a universal COVID-19 vaccine recommendation (except for HHS’ recent change for healthy children and pregnant women) to “shared clinical decision-making”, including for those 65 and older, along with a recommendation for new language on risk-benefit for COVID-19 vaccinations. ACIP’s recommendations were adopted by CDC on October 6. While the separate MMR+V vaccines had been recommended as preferred by the CDC for many years, the combination MMRV provided an option for parents to reduce the number of injections their children receive. Now, insurers will no longer be required to cover this vaccine at no-cost. The new COVID-19 vaccine recommendations mean people of all age groups are now recommended to have an interaction with a health care provider (which could include a doctor, nurse, or pharmacist) to determine whether getting a COVID-19 vaccination is recommended for them. If that determination is made, insurers must cover the vaccine at no-cost, although it is possible that some consumers may face challenges in accessing providers in the first place or demonstrating that they have consulted with a medical provider seeking vaccination in some cases.    
September 22, 2025President Trump and Secretary Kennedy announce new actions to address autism spectrum disorder in the U.S.
– In a press conference and via an HHS press statement and Fact Sheet, President Trump and HHS Secretary announce several actions to address the issue of autism spectrum disorder (ASD) in the U.S. This includes FDA authorization for leucovorin, a treatment option for some children with autism, a regulatory change that will allow state Medicaid programs to newly cover leucovorin for the indication of ASD. President Trump and Secretary Kennedy also highlight what they say are risks of acetaminophen use during pregnancy and association with autism. The press release notes “HHS wants to encourage clinicians to exercise their best judgment in use of acetaminophen for fevers and pain in pregnancy by prescribing the lowest effective dose for the shortest duration when treatment is required.”  In his remarks, President Trump also implicated childhood vaccines as a potential risk factor for autism, though no new evidence was presented and that link has already been repeatedly and conclusively ruled out. In a subsequent press statement on September 22, HHS announced FDA was initiating a labeling change for leucovorin, and a safety label change for acetaminophen to include information about the “potential risks of acetaminophen so patients can make a more informed decision.” Public health groups and experts criticized the conclusions linking acetaminophen use in pregnancy and autism, and expressed doubts about leucovorin as a treatment for autism. President Trump’s remarks also precipitated a lawsuit filed on October 28 in Texas against the maker of Tylenol.
September 30, 2025FDA approves a new generic mifepristone product.
– The FDA approved Evita’s Solutions application for a generic version of mifepristone.   The approval included a reminder that the generic mifepristone is subject to the same  Risk Evaluation and Mitigation Strategy (REMS) as the brand-name.
September 30, 2025HHS awards $60 million in grants to support prevention of falls and related programs for older adults and those with disabilities.
– Secretary Kennedy announced 59 new grants totaling $60 million is being awarded to states, territories, tribes, and local organizations supporting older adults and Americans with disabilities, including programs for “preventing falls among seniors, managing chronic conditions…and funding dementia-capable programs.”
October 10, 2025Trump Administration fires thousands of HHS employees, including hundreds at CDC, during federal government shutdown.
– In the midst of a government shutdown and an ongoing federal funding impasse in Congress, the White House Office of Personnel and Management says over 4,000 federal workers are to be fired. At HHS, over a thousand workers are notified that they have lost their jobs, with most of those losses concentrated at CDC. Some of those job losses were reversed over the next few days, with HHS officials stating some notices were sent in error. Even so, as of October 14 it is estimated that about 600 CDC employees remain fired, including staff in areas such as injury prevention, health statistics, and Congressional relations. There is a question about whether such firings during a government shutdown are legal, and groups representing federal workers have filed lawsuits to halt these mass layoffs.
October 31, 2025FDA announces new restrictions on ingestible fluoride products for children.
– FDA announces new enforcement actions “to restrict the sale of unapproved ingestible fluoride products for children” and sends letters to health care professionals warning about the risks associated with these products. The actions come after FDA conducted a review and published a scientific evaluation of these products. In the announcement. FDA says it will be developing a “fluoride research agenda” and “the first national oral health strategy” for the U.S. in partnership with NIH and other HHS agencies.
November 10, 2025FDA announces a warning label change on hormone replacement therapy (HRT) products for addressing symptoms of menopause.
– In a press release, a fact sheet, and a live press event, FDA leaders announce that they will initiate the removal of broad “black box” warnings from HRT products for menopause. The FDA also announces approvals for two new drugs for menopausal symptoms. According to the FDA, women have been “under-utilizing approved therapies” since the “black box” warnings about risks associated with the drugs were placed on these products over 20 years ago. Labels will be rewritten with guidance saying that there are long-term health benefits if HRT is begun within 10 years of the onset of menopause.
November 19, 2025CDC changes language on its website to say a link between vaccines and autism cannot be ruled out.
– A CDC website providing information to the public on Autism and Vaccines, is changed to include language saying “studies have not ruled out the possibility that infant vaccines cause autism.” The new site also discusses the “state of the evidence” on common childhood vaccines and supposed links to autism. The new language is a reversal from previous CDC statements saying “vaccines do not cause autism,” and contradicts the long established scientific consensus that there is no link between vaccines and autism. The new CDC webpage language has been criticized by professional medical organizations such as the American Medical Association and the American Academy of Pediatrics, as well as autism organizations such as Autism Speaks and the Autism Science Foundation.
November 21, 2025CDC staff ordered to end all monkey research programs, potentially affecting development of prevention tools for HIV and other infectious diseases.
– According to reports, CDC staff are ordered to halt its monkey research program by the end of 2025. This program has helped develop HIV prevention tools such as pre-exposure prophylaxis (PrEP) and microbicides, as well supported prevention research for other infectious diseases.
November 28, 2025Internal FDA communication proposes stricter federal requirements for testing and approving vaccines.
– According to reports, the head of FDA’s Center for Biologics Evaluation and Research (CBER), which is responsible for regulating vaccines, issues an email to staff proposing new, stricter federal requirements for vaccine testing, evidence, and approval. The email states that in the future FDA will “demand pre-market randomized trials assessing clinical endpoints for most new products” and that FDA “will not be granting marketing authorization to vaccines in pregnant women” without this kind of evidence. Newly developed pneumonia, influenza, and COVID-19 vaccines are specifically mentioned as vaccines that would be subject to these new requirements. The rationale given for this policy change is a new analysis of vaccine safety data indicating “COVID-19 vaccines have killed American children,” though no evidence to support that statement is provided in the email.
December 5, 2025ACIP votes to end recommendation that all newborns receive hepatitis B vaccine dose at birth
On the second day of the Advisory Committee on Immunization Practices’ (ACIP) December 4-5 meeting, members vote to end a long-standing recommendation that all newborns in the U.S. receive a dose of hepatitis B vaccine. The committee now recommends parents of infants born to mothers who test negative for hepatitis B consult with their provider to help decide if and when their child should receive the first hepatitis B dose. ACIP continues to recommend that infants born to mothers who test positive for hepatitis B, or whose hepatitis B test status is unknown, receive the first hepatitis B vaccine dose at birth. A recommendation from ACIP becomes part of the official CDC immunization schedule once it is adopted by the CDC director.
December 30, 2025HHS ends certain requirements for state reporting of immunization data to the Centers for Medicare and Medicaid Services (CMS).
December 30 letter from the Centers for Medicare and Medicaid Services (CMS) informs state health officials that starting in 2026, states will no longer be required to report several measures related to immunization status to CMS. Specifically, CMS removes the following from its “Child and Adult Core Sets”: “Childhood Immunization Status”, “Immunizations for Adolescents”, “Prenatal Immunization Status: Under Age 21”; and “Prenatal Immunization Status: Age 21 and Older.” In addition, in its letter CMS informs state health officials it will “explore options to facilitate the development of new vaccine measures that capture information about whether parents and families were informed about vaccine choices, vaccine safety and side effects, and alternative vaccine schedules” and “how religious exemptions for vaccinations can be accounted for.” Data reported by states and included in the Child and Adult Core Sets are used by Medicaid and CHIP to monitor access to and quality of health care for their beneficiaries, so an absence of this data could make monitoring immunization coverage in this population more challenging.
January 5, 2026HHS announces changes to the federal childhood vaccination schedule that reduce the number of routinely recommended vaccines
Health and Human Services (HHS) issues a memo implementing major changes to the government’s recommended vaccination schedule for children. Under the new guidelines, there are vaccines for 11 diseases recommended for all children, down from 17 diseases a year ago. In addition to COVID-19 (which HHS stopped recommending for all children back in October 2025), the new schedule no longer recommends routine vaccinations for five other diseases: rotavirus, COVID-19, influenza, hepatitis A, hepatitis B, and meningococcal. These vaccines have been moved from routine recommendation to “shared clinical decision making,” a process that is “individually based and informed by a decision process between the health care provider and the patient or parent/guardian.”  The HPV vaccine remains recommended for routine vaccinations, though under the new guidelines HHS reduces the number of recommended doses of HPV drops from two or three (depending on age of initial vaccination) to one. Coverage for all of these immunizations should remain the same through public and private insurance mechanisms. On March 16, 2026, a federal judge issued a ruling that stayed changes to the vaccine schedule from being implemented, as the government did not follow required procedures. On April 29, HHS appealed the judge’s stay and court review continues.
February 3, 2026BARDA opens solicitations for a $100 million prize program for development of novel antivirals targeting dengue, West Nile, and other viruses.
In a news release, HHS’ Biomedical Advanced Research and Development Authority (BARDA) announces it is opening solicitations for a share of a new $100 million SMART Antiviral prize intended to speed the development of “broad-spectrum, small-molecule antiviral therapies” targeting families of viruses that include dengue, Zika, West Nile, and Chikungunya. This first stage is designed to receive solicitations at the concept stage, with solicitations for further development stages anticipated in the future.
February 4, 2026Trump Administration instructs CDC to rescind $600 million in public health funds going to four Democratic-led states
According to reports, the Office of Management and Budget ordered CDC to cut $600 million in funding that had been earmarked for state and local public health programs in California, Colorado, Illinois, and Minnesota. Most of the funding cuts affect programs focused on HIV and STD prevention, are are to be terminated because they “do not reflect agency priorities” according to an HHS spokesperson. On February 11, affected states filed a lawsuit in federal court against these cuts, and on February 12 a federal judge issued a temporary restraining order blocking the cuts from taking effect.
February 10, 2026FDA refuses to review Moderna’s license application for its investigational mRNA-based influenza vaccine
Moderna announces it received a “Refusal to File” letter from FDA stating that the agency will not initiate a review of the company’s biological license application for its investigational mRNA-based seasonal influenza vaccine. According to FDA, the refusal is due to the company’s use of an inadequate comparison arm in its study. Moderna states the letter is “inconsistent with previous written communications” with FDA staff. On February 18, Moderna announced that FDA had reversed its decision, and will now review the application, following further discussions with the company.
February 18, 2026FDA to allow drug approvals with evidence from one clinical trial rather than two
In an opinion article published in the New England Journal of Medicine, FDA leaders announce a new FDA policy that will make the default requirement for FDA approvals to be results from one clinical trial instead of the prior requirement of two clinical trials.  The stated goal of the change is to accelerate the approval and availability of new medicines.
February 19, 2026CDC delays February ACIP meeting
HHS/CDC announces the ACIP meeting previously scheduled for February 25-27 will be postponed. The postponement occurs amid an ongoing federal lawsuit filed by the American Academy of Pediatrics (AAP) and other medical groups that argues the recent revisions made by HHS to the federal child immunization schedule were arbitrary and violated administrative procedures and seeks to have the ACIP panel appointed by HHS Secretary Kennedy removed and replaced and its decisions overturned. On February 26, CDC announced the ACIP meeting had been rescheduled for March 18-19. On March 16, 2025, the judge ruled that 13 of 15 ACIP member appointments did in fact violate administrative procedures and their appointments are stayed along with any ACIP votes since the appointments were made. As a result, the planned March 18-19 ACIP meeting has been canceled.
February 23, 2026FDA launches new framework for speeding development and approval of therapies for rare diseases
FDA announces draft guidance for drug developers that seek approval for targeted, individualized therapies. The new framework outlines new approaches to regulatory review and evidence requirements on the safety and efficacy for rare diseases, given that traditional randomized clinical trials may not be feasible for these conditions.
March 4, 2026HHS Postpones Third Straight Meeting of US Preventive Services Task Force (USPTF)
USPTF, which makes recommendations on preventive health care services, has not met since March of 2026. Five of the 16 USPTF members’ terms have ended as of January 1 and have not been replaced.  
April 10, 2026HHS Publishes Updated ACIP Charter
The Trump Administration published an updated version of the Advisory Committee on Immunization Practices (ACIP) charter. The revised charter features language that broadens the inclusion criteria for ACIP member expertise, including mentions of vaccine safety and recovery from serious vaccine injuries as areas of expertise that members can possess.  The charter language was updated yet again in May, with the newest version published on May 27, 2026. The newest version places oversight of ACIP more directly under the CDC director, includes language that emphasizes potential gaps or limitations in vaccine data, and does not commit to a set schedule of ACIP meetings annually (previously, the charter required three ACIP meetings a year).
April 22, 2026CDC Study on COVID-19 Vaccine Effectiveness Held Back From Publication
Reports find that Jay Bhattacharya, who is overseeing CDC operations while the Director position remains unfilled, held back publication of a CDC study on the effectiveness of the COVID-19 vaccine over the 2025-2026 winter season. The study was scheduled to be published in the CDC’s flagship MMWR publication on March 19, but Bhattacharya objected to the study’s design, although it is a very common design that has been used to study vaccine effectiveness in dozens of prior published studies. The study had found vaccination cut the likelihood of emergency visits due to Covid by 50 percent and of hospitalizations by 55 percent. Eventually, the study was published in a different journal in June 2026.
May 29, 2026 Executive Order On Childhood Vaccines Directs HHS to Review and Update U.S. Childhood Vaccine Schedule
The White House issues an executive order titled “Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries” that instructs federal agencies, including HHS, that the childhood vaccine schedule “should be aligned with scientific evidence and best practices from peer, developed countries while preserving access to vaccines currently available to Americans.” This follows an earlier memorandum from December 5, 2025 instructing HHS to align the childhood vaccine schedule with that of “peer, developed nations.”
June 18, 2026FDA Advisory Committee Unanimously Recommends Approval of mRNA Influenza Vaccine
The Food and Drug Administration’s (FDA’s) Vaccines and Related Biological Products Advisory Committee (VRBPAC) votes unanimously to recommend approval of Moderna’s mRNA vaccine candidate for older adults. In February of this year FDA had said it would not review Moderna’s application for this vaccine, but several weeks later reversed course and agreed to review after Moderna proposed a revised approach to regulatory review. The FDA reports it is likely to make its decision on this vaccine by August 5 this year.
June 30, 2026Secretary Kennedy Terminates COVID-19 Emergency Use Authorization Declarations for Drugs, Biological Products, and Medical Devices
HHS announces Secretary Kennedy has terminated COVID-19 Emergency Use Authorization (EUA) declarations for drugs and biological products and for medical devices after determining these authorizations are no longer needed. The declaration for drugs and biological products will terminate 12 months after the Secretary’s determination, while the declarations for medical devices will terminate 180 days after the Secretary’s determination. EUAs for COVID-19 vaccines had already been terminated.
August 10, 2026Executive Order on Vaccines Instructs HHS and States to Realign Childhood Vaccine Recommendations
The White House releases a new Executive Order (EO) titled “Delivering Gold Standard Childhood Vaccine Recommendations for Americans” that states U.S. childhood vaccine recommendations should be “aligned with scientific evidence and best practices from peer, developed countries,” and sets out three categories of recommended immunization (echoing the January 5 HHS memo described above that issued a new federal childhood vaccine schedule, which has been put on hold by a federal judge). The new EO also directs the HHS Secretary to offer some childhood vaccines such as measles, mumps, and rubella (MMR) as “single vaccines rather than combination products,” and to align vaccine recommendations with findings to be released by a federal panel known as the “HHS Task Force on Safer Childhood Vaccines.”